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Background: visceral pain hypersensitivity is a key feature in functional gastrointestinal 
conditions. This condition leads to an exaggerated response to known painful stimuli, or 
chronic pain with no apparent trigger. There is an important paucity of effective clinical 
interventions for visceral pain hypersensitivity.  
Aim: To understand the central nervous system (CNS) control of visceral pain 
hypersensitivity via descending pain pathways to the spinal cord. Additionally, I aim to 
test the feasibility of a non-pharmacological intervention such as non-invasive vagal 
nerve stimulation to reduce this condition in healthy humans.  
Methods:  I used PRISMA guidelines for systemtic review and meta-analysis to 
investigate: i) decending pain control in visvceral pain, ii) The antinociceptive effect of 
vagal nerve stimulation. To investigate the descending pain control, I used a Conditioned 
Pain Modulation Paradigm where applying a second painful sitmuls inhibits the initial 
pain by triggering descending inhibiton. To test the effect of autonomic modulation on 
oesophageal pain hypersensitivity, I used a previously approved noninvasive 
transcutaneous vagal nerve stimulation device in a human model of experimentally 
induced pain hypersensitivity by slow infusion of hydrochloric acid in the distal 
oesophagus.  
Results: My systematic review and meta-analysis demonstrated that Conditioned Pain 
Modulation is significantly inhibited in visceral pain hypersensitivity. I also showed that a 
reduced Conditioned Pain Modulation at baseline is a strong predictive factor of 
developing pain hypersensitivity in healthy humans. I also demonstrated that vagal nerve 
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stimulation is effective in various pain conditions in a meta-analysis, I then demonstrated 
in an experimental study that vagal nerve stimulation can reverse acid-induced 
oesophageal pain hypersensitivity.   
Conclusions: there is a marked reduction in descending pain inhibition in visceral pain 
hypersensitivity. Poor descending pain inhibition is associated with developing 
experimental pain hypersensitivity. Vagal nerve stimulation can reverse experimental 
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Pain is a defining symptom in many functional gastrointestinal disorders. Those disorders 
are very common. For example, Gastroesophageal reflux disease has a prevalence in 
Europe of 8.8-25.9%, with 10-40% of patients complain of persistent pain or discomfort 
despite adequate acid suppression, indicating important functional component (9).  
The main aim of this thesis is to understand clinically relevant aspects of visceral pain 
hypersensitivity (exaggerated pain responses) with a special focus on the central aspect 
of hypersensitivity, such as the top-down control of pain. I also attempted to understand 
the rationale and the feasibility of using the autonomic nervous system as a portal to 
modulate visceral pain hypersensitivity.  
I take a special interest in oesophageal pain hypersensitivity and use this as a model 
whenever it is possible. However, being a less studied subject, I used other functional 
gastrointestinal disorders with pain hypersensitivity to infer relevant conclusions on pain 
processing. 
In the 1st chapter, I introduce relevant notions of the pain (nociceptive) system, the 
autonomic nervous system and the interaction between the two systems which are 
important for the understanding of the thesis.  
In chapter 2, I present my 1st experimental study. In this study, I studied the autonomic 
signature of two interventions, previously known to have an analgesic effect on 
experimental visceral pain. These interventions include slow deep breathing and 
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modulation of attention. In this study, I aimed to determine whether a shared autonomic 
mechanism may explain the analgesic effect of interventions.  
In chapter 3, I explore the top-down (brain-gut) modulation of pain control. This chapter 
is a meta-analysis to investigate if the top-down inhibition of pain is affected in visceral 
pain conditions.  
Chapter 5 is an experimental study to understand the relationship between experimental 
pain hypersensitivity and the descending pain modulation (top-down control) of pain in 
a human model of oesophageal pain hypersensitivity.  
Chapter 5 is a systematic literature review and meta-analysis of the effect of vagal nerve 
stimulation on pain in general. In this chapter, I show that vagal nerve stimulation is an 
effective treatment in various pain conditions. I then, in chapter 6, use vagal nerve 
stimulation in an experimental study to influence oesophageal pain hypersensitivity in 
humans.  








Chapter 1  
The nociceptive and the autonomic nervous system 
Introduction  
This chapter aims to introduce topics relevant to this thesis such as pain transduction, 
transmission and perception. This chapter is not a comprehensive literature review of 
the physio-pathology of pain in general but a more focused overview of nociceptive pain 
which is relevant to this thesis.  
The nociceptive system 
Pain is defined by the International Association for Study of Pain as an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage(10). It is an 
undesirable, disagreeable sensation (11). It serves to protect the body from potentially 
harmful events (12, 13). The main survival aim of pain is to remove the body away from 
the noxious stimulus voluntarily. 
Types of pain 
Pain is classified in a variety of ways. In reality, these categories often overlap. Some 
classifications are more useful than others depending on the focus of the subject.  
Acute pain and chronic pain 
Acute pain is of short duration, has an apparent underlying causative event and may 
signify healing or a damage control process following that event (14, 15). Chronic pain 
may not have an obvious underlying cause. It usually extends beyond the reasonably 
expected time for tissue healing (16). This distinction is useful in a clinical setting; acute 
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pain requires more urgent management since its cause may be fatal or the cause of long-
lasting disability (15). Chronic pain may be defined as pain lasting more than three 
months, according to the International Association for the Study of Pain (IASP) (16). 
However, somatic, acute and chronic pain differ in nature as well; acute pain may be 
described as sharp,  pricking or stabbing sensation, while chronic pain is often said to be 
slow, aching, or burning (13, 15, 16). 
Nociceptive pain 
Nociceptive pain is experienced when sensory pain receptors (nociceptors) in tissues are 
stimulated. It is further classified into fast or first physiological pain and slow or second 
pathophysiological pain (15). Fast pain is felt in healthy tissue within a tenth of a second 
upon an acute painful stimulus, such as the application of an electric shock or sharp 
object (14, 15). Slow pathophysiological pain corresponds to tissue damage and may 
occur following the stimulus, with a milder or different type of stimulus, or even without 
a stimulus, and this is probably due to sensitisation(13). Fast pain is usually only felt in 
superficial tissues, whereas slow pain is also experienced in deep tissues. The character 
of slow pain is usually similar to that of chronic pain (13, 15, 17). 
Nociceptive pain can also be described as either somatic or visceral pain (15). Somatic 
pain is easily localised, while visceral pain is difficult to describe as restricted to a specific 
body part, and often said to be “generalised” (18). The reason for this may be that there 
are fewer visceral sensory nerves than somatic sensory nerves and fewer visceral pain 
pathways in the central nervous system (18). The automatic reflexes elicited by visceral 
pain are often more prominent than those elicited by somatic pain (18). Inflammation 
plays an important role in the modulation of nociception. Release of inflammatory 
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mediators (ex: substance P, prostaglandins, serotonin, acetylcholine, bradykinin) 
sensitise the primary afferents resulting in a reduction if pain threshold (19).  
Neuropathic pain 
Neuropathic pain is now defined by the International Association for the Study of Pain 
(IASP) as ‘pain caused by a lesion or disease of the somatosensory nervous system’(10). 
Neuropathic pain could affect both, the central or the peripheral part of the 
somatosensory system.  Damage to the peripheral sensory nerves could result in chronic 
pain secondary to diabetic, or alcoholic neuropathy, radiculopathy, trigeminal neuralgia 
and other debilitating conditions. Neuropathic pain can also arise at the level of the 
central nervous system such as  in multiple sclerosis, spinal injury or after stroke(20).  
The nature of the sensation is often distinct from that of the nociceptive pain, it is usually  
described as “burning” or “electrical” (13).  
 
Nociplastic pain  
Nociplastic pain is a new category of pain added to the 2017 taxonomy of the 
International Association for the Study of Pain (IASP) (10).  It refers to the activation of 
nociceptive receptors without clear evidence of tissue damage. It is most likely related 
to altered nociception. Examples include low back pain, complex regional pain syndrome 




Primary and Secondary Chronic Pain  
This classification is on the latest International Classification of Diseases ICD11(21). 
Primary (idiopathic) chronic pain, overlaps with the nociplastic pain classification 
mentioned above.  Primary chronic pain is recognised as a disease in itself such as low 
back pain, fibromyalgia and pain in functional gastrointestinal disorders. Whereas, 
secondary chronic pain is a symptom of an underlying condition such as cancer pain, 
neuropathic pain caused by multiple sclerosis and other chronic pain with a known 
aetiology  (22, 23).  
 
Pain pathways and systems 
Overview 
Nociception involves the signalling of pain (12). The nociceptive system refers to the 
entire system responsible for collection, transmission and processing of pain signals (13). 
Traditionally, those pathways are investigated by electrophysiologic studies in animals 
such as single unit recording by invasive electrodes(24-28). However, other methods 
such as functional Magnetic Resonance Imaging (fMRI) and Electroencephalograph (EEG) 
have also been used to map those pathways in humans (13, 29-31). 
The first-order neurons are nociceptors in peripheral tissues, the axons of which synapse 
with neurons in the dorsal horn of the spinal cord (13, 14). These second-order neurons 
either directly ascend to higher centres in the brain or interact with spinal neurons (13). 
Peripheral transmission of pain 
Primary afferent neurons carrying pain signals are pseudo unipolar neurons with their 
cell bodies in the trigeminal or dorsal root ganglion (17). 
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Types of nociceptors 
Nociceptors are sensory pain receptors in peripheral tissues(14). They consist of the free 
nerve endings of first-order neurons and are sensitive to a variety of stimuli including 
mechanical, thermal and chemical events (12, 14). We may classify nociceptors based on 
the type of stimulus they respond to, the type of nerve fibre (A or C), and whether they 
are silent or not(17). Silent (“wide-dynamic range” or “convergent”) pain receptors are 
usually unresponsive to temperature and pressure, but become active to these stimuli if 
sensitised by molecules involved in inflammation (substance P, prostaglandins, 
serotonin, acetylcholine, bradykinin)  (17, 32).  
For example, nociceptors in the oesophagus respond to acid by activating two proton-
gated channels: transient receptor potential vanilloid-1 (TRPV1- thermal) and acid-
sensing ion channels (ASICs- chemical), while mechanical nociceptor such as TRPAI can 
detect distention (33). 
 
Peripheral pain fibres 
Fast and slow types of pain travel through different fibres to the spinal cord. Fast pain is 
transmitted through myelinated A fibres (the majority of which are A-δ fibres) at a 
velocity of 5m/s to 30m/s, which is faster than the transmission of slow or chronic pain 
through unmyelinated C fibres at 0.4m/s to 1.4m/s (17, 34). This transmission occurs 
simultaneously via both fibres when the same acutely painful stimulus is applied, 
resulting in a dual sensation of nociceptive pain; a sharp pain, followed by a lingering dull 
pain (15, 17). 
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A-fibres are clustered in groups, with each group serving a small location, and distributed 
less widely than C fibres, making fast pain localisation more precise than that of slow 
pain (17). 
Aδ and C fibres travel to superficial and deep spinal cord laminae (Rexed’s laminae I, II 
and V, VI; circumcanular lamina X) while Aβ fibres (the largest in diameter of these three 
types of fibres) mainly travel to the deep Rexed’s laminae (III to VI) (32). 
Central transmission of pain 
When they reach the dorsal horn of the spinal cord, primary afferent neurons may 
synapse directly with neurons projecting to higher centres, or with interconnecting 
neurons in the spinal cord (11). These interneurons may be excitatory or inhibitory. 
Inhibitory interneurons can exert their effects on projection neurons (PNs), excitatory 
interneurons or the first-order neurons to dampen their actions (15, 32). The main 
neurotransmitters in descending inhibition are opioids and noradrenaline, while the 
main excitatory neurotransmitter is Serotonin or 5-hydroxytryptamine (5-HT). First-
order neurones may also send ascending and descending collaterals, and these branches 
form the dorsolateral tract of Lissauer (35). After entering the dorsal grey matter, 
second-order neurons arise from Rexed’s laminae, decussate (crossover) and ascend in 
the anterolateral spinal cord (35). Two main tracts carry pain signals from the spinal cord 
to the higher centres, called the neospinothalamic and palaeospinothalamic tracts (35). 
Interestingly, these tracts are named according to their evolutionary origin; the 
palaeospinothalamic tract has a more primitive origin, and perhaps this reflects the types 
of sensations this tract carries; slow poorly localised pain (36). The spinoreticular, 
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spinomesencephalic and spinohypothalamic pathways also carry pain signals to the brain 
(11, 37). 
Neospinothalamic tract 
Fibres from the periphery synapse in laminae of the dorsal horn, from where central 
neurons arise to form the neospinothalamic tract (15). The projection neurons promptly 
decussate and ascend in the anterolateral column of the spinal cord to the brain (15). A 
few fibres terminate in the reticular formation of the brain stem, and some other 
neurons wind up in the posterior nuclear group of the thalamus, but the majority 
terminate in the ventrobasal thalamus (15). 
Palaeospinothalamic tract 
The spinoreticulothalamic or palaeospinothalamic tract is formed from the deeper 
laminae of the spinal cord (15, 36). Pain signals follow a path similar to that for fast pain, 
as projections first decussate, then ascend in the anterolateral column of the spinal cord 
(15). Unlike the neospinothalamic pathway, however, at least three-fourths of the fibres 
terminate in the reticular formation, tectal area or the periaqueductal grey area of the 
brainstem with the remainder ending up in the thalamus (15). Pain is then further 
transmitted to basal portions of the brain through several neurons; however, chronic 
pain is still felt when these higher centres are sectioned in animals, underlining the 
importance of the basal areas in interpreting chronic pain (15). Please notice that these 
basal structures play an essential role in the autonomic refluxes as I will elaborate later 




Pain is modulated in a variety of ways, both centrally (such as via descending facilitatory 
and inhibitory pathways from higher centres-explained later) and peripherally (by the 
sensitisation of receptors) (11, 13, 32). Thus, the intensity of pain experienced by an 
individual can vary even with an identical set of stimuli. 
Pain experience differs from individual to individual; however, depending on the 
circumstances, such experiences may also differ within the same individual. The 
difference is sometimes remarkable; for example, soldiers may report little pain to gun-
shot wounds during the battle (38). Such variability in pain experience is possible due to 
a complex pain control system that intervenes at multiple levels; from pain conduction 
at the periphery, transmission to the central nervous system, to the processing of such 
stimuli at cortical levels. 
Peripheral and central sensitisation 
Central sensitisation is defined as an ‘’increased responsiveness of nociceptive neurons 
in the central nervous system to their normal or subthreshold afferent input’’. While 
Peripheral sensitisation is defined as ‘’increased responsiveness and reduced threshold 
of nociceptive neurons in the periphery to the stimulation of their receptive fields’’(10, 
39). See figure 1.  
Sensitisation of nociceptors 
Most sensory receptors in the body adapt to their excitatory stimulus (15). However, 
nociceptors undergo little or no adaptation, allowing pain to be felt continuously as long 
as the precipitating condition is present (15). Paradoxically,  in many cases of chronic 
pain, pain receptors undergo sensitisation as the stimulus persists (11). 
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There are various ways in which receptors can become more sensitive to pain. In some 
cases, the same receptor undergoes sensitisation (for example, silent receptors 
becoming active). This causes hyperalgesia (exaggerated response to a painful stimulus). 
Repetitive activation of nociceptors can cause central sensitisation at the level of the 
spinal cord leading to a progressive increase in pain intensity with the same stimulus. 
This central phenomenon is called temporal summation, which is one manifestation of 
hyperalgesia (11). 
 In other cases, surrounding receptors which may not even be “nociceptive” in nature 
(silent nociceptors) can begin to transmit pain, for example, mechanical allodynia (a 
painful response to non-painful stimuli, for example, painful touch)(11, 32). The 
activation of silent nociceptors is also one of the mechanisms for central 
sensitisation(11).  
Allodynia can be explained by Aβ fibres which are responsible for a shift in the phenotype 
of first-order neurons so that they begin to produce excitatory molecules normally 
involved in pain signalling (11, 32). Besides, receptor neurons that undergo damage may 
be reorganised, placing primary sensory neurons in communication with ascending 
neurons and bypassing the normal dampening mechanisms of painful signals at the level 
of the spinal cord (32). This bypass mechanism might answer why traditional analgesics 
are not effective in relieving allodynia after nerve damage or neuropathic pain and 
suggests as a solution that we explore therapies targeting ascending neurons (32). 
Descending tracts may cause sensitisation to pain in silent or wide-dynamic range 
receptors in several ways. This sensitisation occurs when a pain stimulus is repeatedly 
provided. One possibility of how this happens is unique communications between 
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descending pathways and primary afferent fibres (which may or may not involve 
inhibitory interneurons) (32). Another possibility is the inhibition of excitatory neurons 
that relay with projection neurons (32). Projection neurons may also be directly acted 
upon by descending tracts at specific loci physically shared with primary sensory neurons 
(32). Some believe that the ascending pain signals carried by projection neurons may be 
modified by intracellular signalling pathways that are acted upon by descending control 
(32). The clinical importance of studying these processes is that when looking at patients 
who exhibit this type of sensitisation, one needs to target therapies that will alleviate 
pain but not dampen the other senses which could prove challenging (32). 
 
 
Figure 1: Peripheral and central sensitisation. Peripheral sensitisation refers to the increase in pain 
transduction at the level of the nociceptors, and this increase is usually triggered by tissue damage or 
inflammation with the release of local mediators such as Substance P, Prostaglandins, serotonin and 
acetylcholine. Central sensitisation refers to the increase in pain transmission at the level of the spinal cord. 
Perception of pain at the level of the spinal cord can, in turn, alter the overall experience of pain. Adapted 




Gate control theory of pain 
The gate control theory of pain was initially drawn up by Melzack and Wall (41) and 
proposed that peripheral pain signals to the central nervous system are “gated” in the 
spinal cord by various influences (42). These influences are provided by the cells in the 
substantia gelatinosa of the spinal cord (41). The non-painful sensory neurons projecting 
to the spinal cord can compete with painful stimuli to pass the “gate” and ascend to 
other structures (41). The gate control theory of pain is the main theory relied upon 
when explaining the antinociceptive effect of non-painful stimuli, such as massage and 
acupuncture. Since the proposal of this theory, our understanding of pain control has 
come a long way. Advances in the neurobiology of pain has implicated several synergic 
mechanisms that may determine the size of the ‘’gate opening’’. One of the factors that 




Descending control refers to the ability of higher structures to inhibit or facilitate 
receptive pain fields at the spinal cord (32). See figure 2.  
Descending pathways may interfere with primary sensory neurons (“pre-synaptic 
actions”), or spinal interneurons or projection neurons in the spinal cord (“post-synaptic 
actions”) (32). When descending inhibition acts upon an interneuron that has an 
inhibitory nature in itself, either a different neurotransmitter is used, or the usual 
neurotransmitter acts via different second receptor and coupling mechanisms (32). Thus, 
it follows that the same neurotransmitter may have opposing functions; for instance, 
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serotonin (5H-T) may exacerbate or attenuate nociception in the spinal cord (32). It also 
follows, in theory, that drugs targeting specific receptor types or second messengers can 
provide pain relief with a high efficacy (32). 
Apart from direct synapses between descending tract neurons and sensory neurons, 
“volume transmission” also takes place in the spinal cord (32). Volume transmission is a 
way of intracellular communication by means of diffuse neurotransmitter in the 
extracellular fluids, it is roughly analogous to injecting drugs into the spinal cord. 
Neurotransmitters such as dopamine and glutamate diffuse locally after their release, 
resulting in broad and lingering effects on nearby synapses or other cells in the vicinity, 
such as adjacent astroglia  (32, 43). These effects are, to a good extent, dependent on 
the pharmacokinetic properties of the transmitter molecules (32).  
Neurons are not the only spinal cord cells involved in descending control of pain. 
Descending tracts also affect spinal glial cells and invasive T cells, both of which produce 
substances that can modify pain transmission (32). For example, glial cells produce an 
acetylcholine-binding protein that can affect autonomic signalling (32). 
Motor responses to pain, such as reflexes and the promotion of motionlessness to 
improve healing are also influenced by descending control on the ventral horn of the 







Figure 2: Schematic representation of the descending pathways. Several structures contribute to the origin 
of the descending pathways such as rostroventral medulla (RVM) and other brainstem nuclei, the nucleus 
tractus solitarius (NTS), the parabrachial nucleus (PBN), the dorsal reticular nucleus (DRT), the 
hypothalamus and the cortex. The separation of the descending pathways into facilitatory and inhibitory 
pathways is functional rather than anatomical. The descending pathway can alter pain transmission at the 
level of the primary afferent neuron, projection neuron or by activating interneurons (excitatory or inhibitory).  
 
Types of descending control 
Although, the same structures are involved in descending control, functionally there are 
two distinct pathways according to the type of influence they exert on pain processing 
in the spinal cord, descending facilitation and descending inhibition (32). As described 
above, the same neurotransmitter may modulate actions in both of these pathways 
simultaneously via different receptor neurons or different receptor types (32). 
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The rostroventromedial medulla has been extensively studied in this regard (32). There 
are two kinds of neurons recognised in the rostroventromedial medulla, “OFF” cells and 
“ON” cells (32). “OFF” neurons are involved in descending inhibition, are stimulated by 
opioid analgesics and upon receiving sensory pain input, pause their discharge before a 
pain reflex (32). “ON” cells behave oppositely and are implicated in descending 
facilitation (32). 
Origin of the descending pathways 
Central structures from which descending pathway neurons project to the dorsal horn 
are the hypothalamus, parabrachial nucleus, nucleus tractus solitarius, brainstem nuclei, 
cerebral cortex (frontal, parietal and anterior cingulate cortex) and periaqueductal grey 
matter (32). These pathways enter the spinal cord through the dorsolateral and 
ventrolateral funiculi (32). 
Hypothalamus 
The hypothalamus plays a significant role in organising sensory information and is well 
connected to the nucleus tractus solitarius, periaqueductal grey matter, 
rostroventromedial medulla and those parts of the corticolimbus that are associated 
with feeling pain and related emotions (32). Hyperalgesia can be elicited by damaging 
the medial hypothalamus and a few other hypothalamic nuclei (32). Several nuclei of the 
hypothalamus give rise to descending pathways which end in the spinal cord, for 
example, the paraventricular nucleus, the arcuate nucleus, the tuberomammillary 




Pathways originating in the parabrachial nucleus mainly influence the nerve cells of the 
superficial laminae of the dorsal grey matter of the spinal cord. Excitation of this area 
dulls the reaction of dorsal horn cells to all types of sensory signals, including pain (32). 
Nucleus tractus solitarius  
The nucleus tractus solitarius is important in managing input from the viscera. It receives 
a large amount of sensory information from the vagal nerve and neurons in the dorsal 
horn (32). 
Brainstem centres  
Monoaminergic pathways to the spinal cord arise from several groups of neurons in the 
brainstem (32). The rostroventromedial medulla receives mostly indirect sensory input, 
and each of its nuclei sends descending pathways to the superficial and deep spinal cord 
laminae; these pathways are considered to essentially cause continued pain in cases of 
inflammation and damage to the nociceptor cells (32). 
The dorsal reticular nucleus of the medulla also has direct connections to superficial and 
deep Rexed’s laminae, some of which are reciprocal, thus forming looped pathways as 
well (32). Hyperalgesia can be caused by dorsal reticular excitation, while damage to this 
structure causes numbing of the pain associated with inflammation (32). Further, it has 
also been suggested that the dorsal reticular nucleus is implicated in “Diffuse Noxious 
Inhibitory Controls” also called Conditioned Pain Modulation, which is analgesia in one 
body areas triggered by a painful stimulus to an anatomically distant area (32). Diffuse 
Noxious Inhibitory Control is discussed further later in this chapter. Unlike the 
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rostroventromedial medulla, the dorsal reticular nucleus is poorly studied concerning 
underlying mechanisms and connections (32). 
Periaqueductal grey matter 
Periaqueductal grey (PAG) is a critical structure in the descending pain control. It receives 
direct and indirect projections from higher structures such as the anterior cingulate 
cortex and amygdala(44, 45).  PAG also receive ascending nociceptive inputs from the 
dorsal-horn via the Parabrachial nuclei. PAG, through its reciprocal connections with the 
RVM, plays a crucial role in the descending modulation.  Activity in the PAG are mediated 
mainly by µ-opioid agonists but also GABAergic inhibitors, cannabinoid receptor agonists 
and results in monoaminergic descending inhibition control via RVM (32, 46).  
Cerebral cortex 
Nociception in the spinal cord can be modulated by even the highest levels in the central 
nervous system. Pain can be inhibited by excitation of the insular and ventro-orbital 
cortex via other areas of the central nervous system discussed above (32). However, 
excitation of other areas, such as the anterior cingulate cortex, has been shown to 
initiate descending facilitation pathways in the rat (32). Functional MRI studies have 
repeatedly implicated the anterior cingulate cortex in pain perception in humans(44, 45).   
Fibres originating from the frontocortical, somatosensory and parietal cortex pass 
uninterrupted to the spinal cord where they act mainly on resident neurons of the dorsal 
horn; however, there are also many multi-neuronal pathways from the cortex to the 
spinal cord (32). Some of these pathways run to the dorsal column nucleus, which is 
known to play a part in both proprioception signalling and the initiation of visceral and 
neuropathic pain (32). 
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Conditioned pain modulation 
One way of assessing descending inhibition is by measuring the conditioned pain 
inhibition. Conditioned pain modulation refers to the endogenous pain inhibition of a 
specific stimulus when a second pain stimulus is applied simultaneously in an 
anatomically distant part of the body. It is evaluated by assessing participant’s pain 
threshold to a specific stimulus (test stimulus), then reassessing it after applying a second 
painful stimulus, also called conditioning stimulus. Following the principle that ‘’pain 
inhibits pain’’. CPM was formally known as Diffuse Noxious Inhibitory Control described 
by Le Bars (47). Diffuse Noxious Inhibitory Control is a specific term that refers to a 
brainstem mediated mechanism. Thus, Conditioned Pain Modulation was adopted as an 
alternative term to incorporate the psychophysiological factors important in shaping this 
type of pain control in humans (48). 
In healthy humans, there is a significant increase in pain threshold to the test stimulus 
after applying a second conditioning stimulus (49). Conditioned pain inhibition is thought 
to be mediated via Diffuse Noxious Inhibitory Control system. In rats, Diffuse Noxious 
Inhibitory Controls is thought to be mediated via neurones in the subnucleus reticularis 
dorsalis (SRD) (50). However, human studies suggest the involvement of other nuclei, 
such as the Periaqueductal grey and structures that allow for interactions with higher 
structures (51). 
Conditioned pain modulation is reduced in a variety of chronic pain conditions such as 
Functional Abdominal Pain, Irritable Bowel Syndrome, Functional Dyspepsia, and other 
conditions such as osteoarthritis, diabetic neuropathy (52-54). This reduction in CPM has 
a large effect size, as confirmed by our meta-analysis in chapter 3 (55).   
38 
 
A reduction in the noradrenergic descending pain inhibition or activation of the 
serotonergic pain facilitation  may play a key role in visceral pain hypersensitivity where 
there is an exaggerated response to a potentially painful stimulus (55). However, more 
work is needed to explain the sequence of events linking visceral hypersensitivity in 
chronic pain conditions, reduced conditioned pain modulation and descending pain 
control.    
 
The autonomic nervous system 
The autonomic nervous system (ANS) is a collection of sensory (afferent) and motor 
(efferent) neurons that link the central nervous system (CNS) with visceral effectors (56). 
Newer definitions recognise the influence of the central nervous system in setting the 
baseline and modifying the activity of the autonomic nervous system (57). 
Classifications 
Langley classified the autonomic nervous system into the parasympathetic nervous 
system which is responsible for the body’s rest and digest function and controls 
homeostasis; the sympathetic nervous system which responds to an emergency that 
causes stress or fear and requires a fight or take flight response (run away); and the 
enteric nervous system, which is also known as the second brain due to its independent 
reflex activity within the gastrointestinal tract (58). The autonomic nervous system is also 




Table 1 describes some of the innervation and functions of the effectors of the 
autonomic nervous system(59). The sympathetic nervous system also innervates the 
pineal gland and lymphatic tissues (60).  
Table 1: Functions of the autonomic nervous system  
 
A dash means the target tissue is not innervated by this division of the autonomic nervous system. Adopted from 





The neurons of the autonomic nervous system synapse at autonomic ganglia; thus, 
presynaptic and postsynaptic neurons are termed preganglionic and postganglionic 
neurons, respectively (57, 60). 
Descending outputs from the CNS to the periphery make up the preganglionic neurons; 
the craniosacral (parasympathetic) outflow and the thoracolumbar (sympathetic) 
outflow (60). The neurotransmitter of presynaptic neurons in both sympathetic and 
parasympathetic is acetylcholine. Norepinephrine is the main postsynaptic transmitter 
in the sympathetic and acetylcholine is released by the postsynaptic parasympathetic 
neurons. 
The vagus nerve is the longest of the cranial nerves. It carries afferent and efferent 
parasympathetic fibers. The main sensory nucleus of the vagal nerve is the nucleus 
tractus solitarius (NTS). NTS receives sensory input from the viscera (32). 
The diagram (Figure3) helps describe the neuroanatomical arrangement of the 




Figure 3: the neuroanatomical arrangement of the autonomic nervous system 
 
Functional anatomy 
Sympathetic Nervous System  
Preganglionic neurons 
The cell bodies of the preganglionic sympathetic neurons lie in the intermediolateral 
column of the spinal cord from the first thoracic to the upper third or fourth lumbar 
segments. These neurons exit the spinal cord in the ventral roots and white rami 
terminate in the sympathetic ganglia as described below, on the enteric nervous system, 




The cell bodies of sympathetic postganglionic neurons are found in the paravertebral 
ganglia, the prevertebral ganglia or the pelvic splanchnic ganglia. The paravertebral 
ganglia form a chain (sympathetic trunks or chains) parallel to the vertebral column, 
which extends on each side to the sacrum. White and grey rami connect them to spinal 
nerves. A majority of the postganglionic neurons travel via the spinal nerves, and the rest 
through splanchnic nerves to supply viscera (60). 
The prevertebral ganglia lie in front of the vertebral column, are unpaired and mostly 
located around the origin of the major branches of the abdominal aorta. The axons of 
the ganglia cells are long and mostly unmyelinated (60). 
The pelvic splanchnic ganglia are located in the pelvic plexus. The preganglionic 
sympathetic neurons that terminate in these ganglia come through via the hypogastric 
nerves (or plexuses) (60). 
Parasympathetic Nervous System  
Preganglionic neurons 
The cell bodies of preganglionic parasympathetic neurons are situated in the 
mesencephalon and the medulla oblongata (tectal and bulbar system) and the 
intermediate zone of the sacral spinal cord (sacral system). The third, seventh and ninth 
cranial nerves deliver them to the parasympathetic ganglia of the head; the tenth cranial 
nerve (vagus nerve) to the ganglia of viscera in the thorax and abdomen; and the pelvic 
splanchnic nerves to the pelvic ganglia. The sacral outflow also consists of preganglionic 




The cell bodies of postganglionic neurons are situated in parasympathetic ganglia in the 
head, in or close to the walls of the target viscera, and in the pelvic plexus (60). Their 
axons are thus often short. 
 
The interaction between the nociceptive and autonomic nervous systems 
 
The nociceptive system and the autonomic nervous system are intertwined and exert 
effects on each other. See Figure 4 for some of the shared structures.  
Descending control and higher autonomic centres 
Several parts of the hypothalamus process sensory and autonomic information. 
Pathways (that likely use glutamine) connect the medial preoptic nucleus (MPN) of the 
hypothalamus to the PAG and the RVM.(32). The MPN and anterior and lateral 
hypothalamus all have an inhibitory effect on pain via descending parasympathetic 
pathways. The PBN and the NTS play similar roles as the hypothalamus with regards to 
the processing and inhibiting pain. The PBN has connections with the NTS, RVM, spinal 
DH and the trigeminal nucleus of the medulla. Although the NTS is usually implicated in 
the inhibition of pain, it has been observed in several studies that vagal input to the NTS 
involving the RVM can cause descending facilitation of pain (32) 
Descending control and spinal autonomic centres 
Certain descending control tracts greatly influence the sacral and thoracolumbar 
preganglionic autonomic ganglia, in particular, those that use 5-HT, noradrenaline, 
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Substance P and thyrotropin-releasing hormone (TRH). This influence must be 
considered when studying these mechanisms, so as not to be confused by results altered 
by cardiovascular (CVS) changes. Autonomic CVS changes, for example, mean arterial 
pressure changes, can alter pain signalling in the spinal cord.  Conversely, this can also 
mean that spinally administered analgesics affect cardiovascular functions. Furthermore, 
ascending vagal fibres to the NTS can exert control over descending tracts via a looped 
pathway (32). 
Descending control and the sympathetic nervous system 
The direction of sympathetic fibres into the spinal cord following sensory neuronal 
damage can cause increased neuropathic pain. Sympathetic changes can also have an 
effect on inflammation and pain in the periphery. Some spinal analgesic drugs, for 









Figure 4: The autonomic and nociceptive networks. In this figure, we notice that the autonomic and the pain 
network share fundamental structures. For example, structures such as Cingulate cortex, thalamus, 
amygdala, periaqueductal grey are shared between the two functional networks.  
 
 
 There are other indirect connections between the pain system and the autonomic 
nervous system; one of those interesting connections is the three-way relationship 
between the autonomic nervous system emotions and pain.  One of those theories that 
may link the autonomic nervous system with emotions and potentially pain is the James-




Nociceptive central network  Autonomic central network  
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The James Lange Theory of Emotion 
Emotions are known to alter the pain threshold. Likely by complex top-down control of 
nociception and by alteration to the cortical processing. Studies suggest a shared 
neuronal network between emotions and the nociceptive system (62). 
The theory of the origin of emotion was first proposed by American psychologist William 
James (1884) and Danish physiologist Carl Lange (1887) independently.  In essence, it 
suggests that emotions are produced by physiological changes such as autonomic 
changes(63). For example, if a person is in a dangerous environment, such as being 
attacked by a predator, subconsciously, that person will recognise the situation as a 
dangerous one, his or her heart will race, breathing will be shallow and rapid. Those 
physiological changes will trigger the emotion of fear. They argue that this is a more 
logical sequence of events(64). Psychology literature is rich in arguments and contra 
arguments for this theory. The theory has important limitations that are out of the scope 
of this theses. However, it emphasises the important observation that there are near-
universal autonomic responses associated with specific types of emotions, such as fear 
and anxiety. 
Another alternative interpretation of how autonomic responses can, by itself, trigger 
emotions is by pavlovian conditioning. Every time a person is in a stressful situation, the 
heart starts to race, the breathing frequency will increase, start sweating, and so on. 
Conversely, whenever a person is relaxed, the opposite of those physiological responses 
take place. Those situations repeat for a staggering number of times throughout our 
lives.  One plausible hypothesis is that if we would design an intervention that mimics 
the autonomic responses of emotion, then we may be able to trigger that emotional 
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status. For example, slow deep breathing, both slows heartbeats and respiration rate, 
leading to a relaxed status that can trigger emotions that are more likely to increase pain 
thresholds and promote analgesia. 
 
In summary, several classifications are used to describe pain, such as acute, chronic, 
somatic, visceral nociceptive, neuropathic and nociplastic pain. Those may overlap. 
Generally, there are three stages in pain-sensing; transduction, transmission and 
processing. Pain regulation depends on several intertwining systems. Higher structures 
send descending pathways to control pain transmission are the level of the spinal cord. 
Cortical, emotional, hormonal and autonomic factors can influence descending 
pathways.  
 
In conclusion, the regulation of pain is complex and involves several interconnected 
pathways. The autonomic and the pain system are structurally and functionally 
intertwined. This relationship may allow for using the autonomic nervous system to 








Aims and Hypothesis  
 
Aims 
In this thesis, I aim to understand the central nervous system (CNS) control of visceral 
pain hypersensitivity via descending pain pathways to the spinal cord. Additionally, I aim 
to test the feasibility of a non-pharmacological intervention such as non-invasive vagal 
nerve stimulation to reduce this condition in healthy humans.  
Hypotheses  
I hypothesise that dysregulation in the descending pain modulation is a key contributor 
to visceral pain hypersensitivity. Moreover, I hypothesis that using electrical stimulation 
of the vagal nerve can modulate the nociceptive system and revere experimentally 

















The autonomic nervous system (ANS) is a complex bodily system, in addition to the 
enteric nervous system, it is comprised of two distinct yet intertwined entities. These are 
the parasympathetic nervous system (PNS) and the sympathetic nervous system (SNS).  
The vagal nerve acts as a key aspect of the PNS, implicated in the homeostatic regulation 
of numerous internal bodily organ systems including the heart, lungs and gastrointestinal 
tract.  Furthermore, the vagus nerve is thought to correspond to the functional state of 
the PNS, and consequently, over the past decades, the degree of vagal nerve activity has 
been quantified in research as differences in interbeat intervals (the time difference 
between two successive heartbeats. One measure of interbeat intervals that reflects 
parasympathetic tone is termed Cardiac Vagal Tone(65). 
 
The PNS has previously been suggested to hold a critical role in the modulation of visceral 
pain, a complex phenomenon that is highly variable and influenced by a multitude of 
inter-individual factors (66, 67). In particular, a link between an individual’s CVT and 
visceral pain perception has been investigated in recent years, leading to the suggestion 
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that an increase in CVT may correspond to a decrease in pain arising from the 
gastrointestinal (GI) tract(68). The proposed anti-hyperalgesic effect of the PNS is 
suggested to mediate through the efferent cholinergic pathway (69).  
Distraction has been used successfully to control pain(70-72). The attention task used in 
this study has an antinociceptive effect at the level of the oesophagus. (30). Coen et al, 
used this task to study visceral pain provoked by balloon distention in the oesophagus. 
The mechanism was suggested to be central, mainly due to distraction.  
Aims  
In this study, we try to determine if there is a shared autonomic response between the 
two analgesic interventions (slow deep breathing and attention) that can contribute to 





The study protocol was reviewed and approved by Queen Mary, University of London, 
UK (reference QMERC2015/55). Besides, both written and informed consent was 
obtained from all study participants before reading the participant information sheet. 
 
Subjects 
Twenty-one volunteers participated in the study, recruited by local advertisement from 
staff and students of Queen Mary, University of London, UK. The study inclusion criteria 
were that of healthy individuals aged 18-60, with a gender distribution ratio not greater 
than 60:40. Women were studied during their follicular phase only to limit the effect of 
endogenous hormones upon autonomic parameters. Furthermore, participants were 
excluded if there was a positive history of anxiety or depression, drug abuse, 
cardiovascular conduction pathologies, or if women were either pregnant or 
breastfeeding. 
 
Twenty-one participants expressed their interest and were subsequently recruited. One 
subject was excluded from all subsequent analysis due to poor data acquisition with 
regard to the autonomic measurements made, leaving a total cohort of twenty healthy 
volunteers (11 male; mean age 24 years, range 20 – 30) was utilised. Participant weight 
and height were recorded, along with the subsequent calculation of body mass index 
(BMI), in order to control for any influence of these parameters upon patient autonomic 
physiology. Mean ± standard deviation (SD) height was 1.70m ± 0.10, mean weight was 
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65.00 ± 13.30 kg and mean BMI was 22.4 kg/m2 ± 3.50 kg/m2, thus it was interpreted the 




For all participants, personality traits and degree of anxiety were quantified using 
validated questionnaires (73, 74). The Big Five Inventory (BFI) was utilised to measure 
the numerical degree of personality traits extraversion, agreeableness, 
conscientiousness, neuroticism and openness, whereby a higher figure represents a 
greater degree of a given trait (73). BFI is scored using a percent of the maximum possible 
score (POMP) system(75).  In addition, state and trait anxiety was quantified using the 
Spielberger State-Trait Anxiety Inventory (STAI) questionnaire (range 20–80, whereby a 
higher score equates to higher anxiety) assessing degree of anxiety on the day of the 
experiment (state (STAI-S)) and general anxiety (trait (STAI-T)) (74).  
 
Autonomic neurophysiology 
Throughout all experiments, ANS data were acquired through a multitude of parameters. 
Some were more specific to the parasympathetic nervous system, such as CVT, some 
were more specific to the sympathetic nervous system, such as cardiac sympathetic 
index (CSI) and, lastly, mixed measures of both arms of the autonomic system were also 
quantified, such as heart rate and blood pressure. These will be described below. 
Importantly, all ANS measurements were recorded in accordance with internationally 





Using the previously validated photoplethysmographic technique (Portapres, 
Amsterdam, Netherlands) (77, 78), real-time arterial blood pressure was measured non-
invasively in the ring finger of the left hand in all subjects, with the arm positioned at the 
level of the heart. Heart rate was also measured continuously, whereby 
electrocardiogram (ECG) electrodes (Ambu Blue Sensor P, Ballerup, Denmark) were 
placed in the right sub-clavicular area, the cardiac apex and left ankle, so as to 
correspond to an axis consistent with Eindhoven’s Lead II. The ECG signal was acquired 
at 5 kHz, by means of a biosignals acquisition system (Neuroscope, Medifit Instruments, 
Enfield, UK), whereby real-time heart rate (HR, beats/min) was quantified by the interval 
between consecutive R waves (R-R intervals, in ms). In addition, raw data was fed into 
the NeuroScope for further processing and real-time derivation of the autonomic indices 
using VaguSoft (Medifit Instruments, London, UK). 
 
Parasympathetic Nervous System Measurements: Cardiac Vagal Tone 
Using the NeuroScope, CVT was measured continuously in real-time, as an index of 
brainstem parasympathetic nervous system efferent activity. A non-invasive continuous 
index of CVT described as pulse synchronised phase shifts in consecutive cardiac cycles 
is a form of pulse interval variability or jitter, was performed in real-time as previously 
described (79, 80). This also facilitates measurements of latencies of responses. The CVT 
is quantified in clinically validated units of a linear vagal scale (LVS) with zero reference 
point, equivalent to full atropinisation in healthy male human volunteers (65). 
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Contrasted to power spectral analysis of HR variability, CVT is validated for time epochs 
of less than 1 minute.  
 
Sympathetic Nervous System Measurements: Cardiac Sympathetic Index 
By calculating the cardiac sympathetic index (CSI), SNS activity was also quantified. CSI is 
derived from a modified Lorez plot of interbeat intervals(81). 
 Following the initial acquisition of R-R interval data, as described above, data was 
reformatted and entered into the Cardiac Metric program (CMetx, University of Arizona, 
AZ, USA). This permits the calculation of the validated Toichi’s CSI, expressed as a ratio 
of R-R intervals, and hence has no units (81). 
 
Study design 
The experimental time course consisted of two separate visits in a crossover design, 
separated by at least one week to permit a ‘wash out’ period for the intervention 
subjects were exposed to. Before patient inclusion in the study, an initial telephone 
screening consultation was performed, to ensure all inclusion and exclusion criteria were 
met (see above). At the beginning of the first visit for any given subject, a 12 lead ECG 
was obtained to screen for any cardiovascular conduction pathologies that may 
otherwise confound results. Furthermore, participants would then complete the BFI 
questionnaire, along with the STAI-T (73, 74). Participants were studied between 0900-
1200 only and were informed to refrain from alcohol and caffeine in the preceding 24 
hours, smoking in the preceding 2 hours, and fast for 6 hours before the study, all of 
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which were undertaken to control for influential variables of autonomic activity. 
Furthermore, all experiments were undertaken in a quiet temperature-controlled 
environment (20 - 22°C). 
 
Experimental time course 
Following the screening consult, subjects were pseudo-randomised to receive one of two 
interventions during their first experimental visit, to which the other intervention would 
be employed during the second visit. The experimental intervention encompassed either 
a paced deep breathing exercise or a distraction task, both of which were 30 minutes in 
duration. Participants were positioned in a chair at 45 degrees, and when all real-time 
data acquisition devices were adequately recording (i.e. with minimal signal 
interference), the three-part experimental design was commenced. All autonomic data 
were acquired continuously throughout. The experimental paradigm was divided into 
the following epochs. Firstly, a 10-minute baseline reading was performed, whereby 
participants were simply told to relax. Following this, the 30-minute intervention would 
commence, either the paced deep breathing or distraction task. Finally, a further 5-
minute baseline period was undertaken. Following this, participants would complete the 
STAI-S, thus concluding the experimental visit. 
 
Deep Breathing Intervention 
For the paced deep breathing intervention, participants would watch and listen to a 30-
minute video whereby they were instructed to mimic the breathing patterns of the 
demonstrator. During the video, 1-minute periods of paced deep breathing would cycle 
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with a 5-minute rest period, when participants were told to breathe normally and relax. 
During the 1-minute deep breathing exercise, the full inspiratory capacity lasted 4 
seconds and was followed by exhalation to forced expiratory vital capacity in 6 seconds, 
repeated at a frequency of 0.1 Hz, thus achieving a rate of 6 breaths per minute. In a 
subsequent analysis of the deep breathing intervention, the exact time course of the 
deep breathing activity was mapped to the beat numbers acquired from the 
Neuroscope, thus permitting data analysis of both the whole 30-minute period 
(encompassing both deep breathing and rest periods), but also during the deep 
breathing exercise only. The utility of paced deep breathing is comparable and validated 
by previously published studies (69, 82). 
 
Distraction Task Intervention 
The 30-minute distraction intervention employed was that of the validated 1-back task 
(Cogstate Ltd, USA). This task involves the presentation of a series of playing cards on a 
computer screen, whereby participants would need to continuously identify whether a 
current and sequential card were the same, or indeed different. Depending on if the 
cards were the same or different, participants were asked to use the computer mouse 
and identify this by clicking either the ‘left’ or ‘right’ button. The card presentation was 
pseudo-randomised and serves as a validated method to ‘distract’ study participants; 





Data distribution was analysed using the Kolmogorov-Smirnov test. Quantitative data are 
herein presented either as mean ± SD, for parametric data, or median with interquartile 
ranges (IQRs) for parametric and non-parametric data respectively. Of note, CVT data 
values were not normally distributed. For non-parametric data, Wilcoxon signed-rank 
tests were utilised to compare CVT during experimental conditions. Furthermore, to 
assess the intervention effects on SNS and mixed measure parameters, repeated 
measures ANOVA were used, with posthoc correction using the Bonferroni method. 
Sphericity was confirmed by Mauchly's test for all ANOVA reports. For CVT and CSI, 
change from baseline was used rather than absolute values  (delta-CVT, delta-CSI), this 
was chosen to reduce inter-individual variability. All statistical tests performed were two-
tailed and statistical significance was thresholded to a criterion of p<0.05. All statistical 
analyses of both psychophysiological and autonomic neurophysiological data were 











Table 2 below summarises the measurements of the autonomic variables during several 
epochs of each intervention.  
 
 
Table 2 : absolute values of autonomic measurements during each intervention and 











Median [IQR]     
                  
9.50 
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8.2 [3.8] 7.7 [3.5] 8.5 [3.7] 8.6 [5]  8.3 [4] 8.7 [6] 
 
Demographics  Age 
[years] 
BMI Weight  Height  Smoking 




65 [13.7]  
kg 
















Parasympathetic effects were measured by cardiac vagal tone. Using Wilcoxon test, SDB 
increased CVT (p= 0.01), Attention task did not affect CVT. However, post-Attention CVT 
was increased (p=0.03). 
  
























Baseline Intervention                  Post-Intervention
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Table 3: Parasympathetic effects. Using Wilcoxon test, SDB increased CVT (p= 0.01), Attention task did 
not affect CVT. However, post-Attention CVT was increased (p=0.03). 
Variable                              Attention 
baseline                 
Attention Post 
attention                 
Breathing 
baseline             
Breathing Post 




[IQR]     
                  
9.50 
[5.25-
11.75]                   
9 [6.25, 
11.75]  























Sympathetic effects were measured by cardiac sympathetic index. ANOVA tests showed 
a significant effect on Cardiac Sympathetic Index (CSI) between interventions, F (2, 38) = 
4.73, p=0.015. Follow-up pairwise comparisons reviled that SDB significantly increased 
CSI (∆= 0.58, CI 0.56-1.1, p= 0.027) 
  

























Table 4: Sympathetic effects. ANOVA tests showed a significant effect on Cardiac Sympathetic Index (CSI) 
between interventions, F (2, 38) = 4.73, p=0.015. Follow-up pairwise comparisons reviled that SDB 
significantly increased CSI (∆= 0.58, CI 0.56-1.1, p= 0.027) 
 
Variable                              Attention 
baseline                 
Attention Post 
attention                 
Breathing 
baseline             
Breathing Post 
breathing         
Cardiac 
sympathetic 




























Mixed effects refer to measurements that are influenced by both sympathetic and 
parasympathetic systems. Those are heart rate and blood pressure.  Attention increased 
both HR and SBP, (∆= 2.9, CI 0.35-5.3, p<0.02), (∆= 10.7, CI 5.2-16.2, p, 0.001) 
respectively. 
  
Figure 7: Systolic blood pressure (SBP) during slow deep breathing (SDB) and attention. Attention 

























Figure 8: Heart rate (HR) during slow deep breathing (SDB) and attention. Attention increased both HR (∆= 


























Table 5. Attention increased both HR and SBP, (∆= 2.9, CI 0.35-5.3, p<0.02), (∆= 10.7, CI 5.2-16.2, p, 
0.001) respectively. 
Variable                              Attention 
basline                 
Attention Post-
attention                 
Breathing 
baseline             
Breathing Post-
breathing         

























All participants completed the BFI and STAI. Of the BFI score dimensions, mean 
extraversion was 28.2 ± 5.9, mean agreeableness was 38.3 ± 5.1, mean 
conscientiousness was 35.3 ± 5.4, mean neuroticism was 16.2 ± 5.3 and mean openness 
was 37.1 ± 4.4. Mean trait anxiety was 46.4 ± 3.6, mean state anxiety after the PDB task 
was 47.6 ± 3.7 and mean state anxiety following the distraction task was 48.2 ± 3.6. 
Anxiety states did not significantly differ following either intervention. After correcting 
for multiple testing, personality trait and anxiety inventory did not correlate with 















Slow Deep Breathing and Attention had distinct patterns of autonomic responses. Slow 
deep breathing activated both the sympathetic and parasympathetic system while the 
significant effect of attention on Cardiac Vagal Tone was restricted to the post-
intervention period; this effect is likely due to relaxation. Attention significantly 
increased HR and systolic blood pressure. During Attention, there was a trend towards 
increasing in Sympathetic Tone and a reduction in Parasympathetic Tone, without being 
statistically significant, likely to be a type 2 error. 
Slow deep breathing caused a pronounced activation of the parasympathetic nervous 
system measured by CVT. This activation was instant, lasted throughout the intervention 
and returned to baseline immediately after the cessation of the task. Attention task did 
not change CVT significantly from baseline. However, there was an increase in CVT after 
the cessation of the task.  
Parasympathetic activation of slow deep breathing is consistent with multiple studies 
that reported a correlation between slow breathing and increased HRV (69, 84-88). 
The parasympathetic activation of slow deep breathing disappeared almost instantly 
after the cessation of the task, suggesting that if long term activation of the 
parasympathetic nervous system is needed, then, longer epochs of slow deep breathing 
might be necessary.  
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Several studies reported a correlation between parasympathetic activity and pain 
thresholds (69, 86, 87). Interestingly, Busch et al., studied the effect of two paradigms of 
slow deep breathing on pain; one task required constant attention while the other was 
aimed to be relaxing, only slow deep breathing with relaxation had an anti-nociceptive 
effect (89).  
Attention, on the other hand, did not significantly alter the cardiac vagal tone. However, 
there was a pronounced post attention activation of the parasympathetic nervous 
system. This increase in cardiac vagal tone is most likely due to relaxation at the end of 
a stressful task. Although, in this study, we did not measure pain tolerance, the role of 
attention in pain modulation is well documented in the literature (30, 90).  It is most 
likely related to distraction from the painful stimulus. This indicates that the 
antinociceptive effect is likely at the level of cortical processing of pain.  
Attention in this study mainly refers to distraction from pain stimulus by shifting the 
attention to another task; it does not refer to attention to the painful stimulus.  
There is some evidence to suggest that interventions combining both breathing 











This study is not without limitations. One of those is the lack of breathing monitoring 
during the attention task. There is a possibility that the autonomic effect of attention 
was driven by changes in breathing pattern due to the difficulty of the task, this change 
in breathing could, in turn, be responsible for the autonomic signature. However, Chang 
et al. showed that attention did not change the breathing rate with mild, moderate and 
intense attention tasks (92). 
The other limitation is the absence of a painful stimulus. The presence of a painful 
stimulus could change the autonomic response.  
 
Conclusions 
The two intervention mounted rather distinct autonomic responses. This finding, making 
it less likely that there is a fixed autonomic behaviour that can change the pain threshold.  
The two interventions are likely to operate via separate mechanisms. Attention is likely 
due to a central mechanism mediated via cognitive structures, likely related to 
distraction. Slow deep breathing antinociceptive mechanism has been suggested to 
operate via the efferent vagal nerve. Botha et al. showed that cholinergic blockade 
diminished the analgesic effect suggesting and efferent mechanism (69).   If the 
mechanism of action is distinct between the two interventions, then a synergic 




Chapter 3  
 
Conditioned Pain Modulation in Irritable Bowel Syndrome; 





The central nervous system can profoundly influence the intensity and hence perception 
of ascending nociceptive sensory signalling. This  ‘descending modulation’ is mediated 
through endogenous pain inhibitory or excitatory pathways (41, 93). A balance between 
those two opposing pathways will determine the nociceptive influx to higher brain 
structures.  Inhibitory pathways are especially important for the scope of this review. 
They mediate a physiological phenomenon termed Conditioned Pain Modulation (CPM) 
where a  painful stimulus can inhibit another existing pain(48).  
Experimentally, conditioned pain modulation can be objectively quantified in three 
steps. Firstly, pain thresholds are measured after an initial test stimulus. Secondly, a 
separate, or what is referred to as a conditioning, a tonic stimulus is applied to an 
anatomically distant region. Finally, the initial test stimulus is reapplied with pain 
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threshold recorded a second time (94). Normally, the pain thresholds between the first 
and second test stimulus increase, when measured at the same time of applying a 
conditioning stimulus. However, in chronic pain disorders, such as migraine, fibromyalgia 
and temporomandibular disorder, pain thresholds to the test stimulus fail to increase in 
the presence of a conditioning stimulus, this, in turn, suggests a degree of deficiency in 
conditioned pain modulation (95-97). Considering that many of these pain disorders are 
frequently comorbid with IBS, it is plausible to suggest that deficient conditioned pain 
modulation may also be important, but under-recognised, a pathophysiological feature 
that contributes to visceral hypersensitivity. Thus, we aimed to address this knowledge 
gap in IBS by performing a systematic review with meta-analysis to assess whether 
conditioned pain modulation is deficient in IBS patients, compared to healthy subjects. 
Secondary aims included investigation of the influence of the diagnostic criteria used to 
define IBS, as well as the predominant bowel habit, on conditioned pain modulation.  
We chose irritable bowel syndrome as a representative of visceral pain hypersensitivity 
because it is the most studied condition in the literature with good quality studies that 
can infer some useful information on the status of conditioned pain modulation in 
functional GI disorders with pain hypersensitivity as the main feature.  
 
Irritable bowel syndrome (IBS) is a common disorder characterised by recurrent 
abdominal pain associated with a change in bowel habit (98). With a reported population 
prevalence of 11.2% (99), it is associated with a significant reduction in health-related 
quality of life and work productivity (100). Heightened sensitivity of the viscera to 
experimental stimulation, referred to as ‘visceral hypersensitivity’, is an important 
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independent contributor to the gastrointestinal (GI) symptom burden of IBS (101). The 
pathogenesis of abdominal pain and visceral hypersensitivity in IBS is complex, 
multidimensional, and incompletely understood (102). However, dysregulation within 
the ‘brain-gut axis’, a bidirectional interface between the brain and the viscera, has been 
implicated (103). Several alterations have been suggested such as peripheral 
sensitisation of nociceptors, low grade inflammation, impaired mucosal function, central 
sensitisation, dysregulated descending inhibition of pain,  perception alterations and 
psychiatric predisposition(102).  
 
Materials & methods 
Search strategy  
We performed a  systematic review and meta-analysis following PRISMA 
recommendations (104). Firstly, we did a literature search using MEDLINE and Web of 
Science (1980 – 10th of May 2018). We searched for studies using the terms 'irritable 
bowel syndrome and functional bowel disorder as a medical subject heading (MeSH) and 
free-text terms. Then, we combined those with the set operator “AND” with following 
terms: diffuse noxious inhibitory control, DNIC, conditioned pain modulation, 
conditioning pain modulation, CPM, heterotopic noxious conditioning stimulation, 
heterotopic noxious counter stimulation, heterotopic nociceptive conditioning 
stimulation, heterotopic nociceptive counter stimulation, descending pain modulation, 
descending pain inhibition, counter stimulation, counter-irritation as free text terms. 
Publications were restricted to those studying adult populations, defined as greater than 
16 years old, with a documented diagnosis of IBS according to any internationally 
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accepted definition of IBS (Manning, Kruis or Rome criteria (i.e. Rome I, II, III or IV)) were 
included. Additional inclusion criteria were: i) use of a conditioned pain modulation 
model; ii) presence of a control group; iii) at least ten subjects in each group and iv) a 
clearly stated outcome measure to calculate conditioned pain modulation. We excluded 
studies if the subjects were taking opioid analgesics or had concomitant chronic pain 
conditions. No language restrictions were set. Relevant studies were independently 
reviewed in full by two investigators (KF and MG). Disagreements were resolved by 
consensus. Conference proceedings from 4 international meetings (Digestive Diseases 
Week, United European Gastroenterology Week, International Association for the Study 
of Pain World Congress and the Joint International Neurogastroenterology and Motility 
meeting) were also searched from 1997-2018. 
 
Outcome assessment 
The name of the first author, year of publication, number of subjects, diagnostic criteria 
used, IBS subtypes, study design and conditioned pain modulation paradigm and 
outcomes were recorded in a standardised fashion using an Excel spreadsheet (Excel for 
Mac 2011, Microsoft, Redmond, USA).  
 
Study methodology quality assessment  
The independent reviewers were blinded to each other’s assessment. The studies were 
assessed for bias in 6 categories; the 1st four categories are adapted from a previous 
meta-analysis that looked at the effect of chronic pain on conditioned pain modulation 
(51). We added two extra criteria that we considered necessary for this type of study; 
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those are the assessment of outcomes and the possibility of co-existence of other painful 
conditions. Each category was numerically graded as 0, 1 or 2, which were considered as 
low, moderate and high risk of bias, respectively. Contingent on these six distinct 
parameters, each study received an overall bias score from 0-12. These categories were: 
1) blinding of assessors (high-risk if un-blinded or not stated); 2) cases representative of 
the population by use of internationally accepted criteria to identify patients (high-risk if 
no criteria were mentioned, moderate risk if specified but not internationally validated); 
3) comparability of cases and controls on age and gender (low risk if <10 %, moderate if 
between 10-20%, high-risk if >20%); 4) controlling for known confounders, including 
menstrual cycle phase; the time of day of assessment; caffeine or alcohol intake; 
presence of other types of pain during testing; attention to the test stimulus/distraction 
from the conditioned pain; medication that could alter the pain perception; 
psychological disorders. If a study controlled for three or more of the confounders then 
it was considered at low risk, if at least two confounders were controlled for in the study, 
then it was considered as moderate risk, and if the study was controlled for 1 or 0 
confounders, then it was considered at high risk. 5) Assessment of outcomes (low risk if 
used a validated conditioned pain modulation paradigm with a painful test and 
conditioning stimulus, high risk if the painful nature of either stimulus is not clear; (6) 
other concomitant disorders of chronic pain (low risk if they were excluded or statistically 
accounted for, moderate risk if it was specified but not excluded and high risk if not 
mentioned in the study).  
In this meta-analysis, we excluded subgroups with concomitant pain conditions or 
psychological factors that may influence conditioned pain modulation, such as in 
Heymen et al. we excluded patients with migraine and temporomandibular joint 
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disorders (105). We also excluded conditioned pain modulation measured inside the MRI 
machine in Wong et al. (106). Wilder-Smith et al. [2014] used two conditioned pain 
modulation paradigms; foot heat and capsaicin as test stimuli (54). However, enough 
data to calculate an effect size was only provided for capsaicin as test stimulus and foot 
heat stimulation as conditioning stimulus, and thus only this paradigm was used in this 
meta-analysis (54). 
We excluded Wilder-Smith et al. [2004] from the meta-analysis because it did not 
provide means and SDs, but medians and interquartile ranges instead (53). Due to the 
small number of participants in this study (n=10 in each arm), it was not technically 
possible to convert this into means and SDs to calculate an effect size necessary for the 
meta-analysis or use other data to calculate a pooled odds ratio(107).  
 
Statistical analysis 
Data were pooled by a random-effects model using Der Simonian-Laird weights (108), as 
this was considered the most plausible methodology given the likely heterogeneity 
between studies and would provide a more conservative estimate of the effect and its 
confidence interval. Data such as group’s means, group’s means before and after 
interventions, standard deviations, p-values and number of participants, were used to 
calculate a standardised difference in means with 95% confidence interval. The 
standardised difference in means was then converted to the natural logarithm of the 
odds ratio using relevant formulas that can be found in this reference(109).  
Outcomes are expressed as pooled odds ratio with 95% confidence intervals (CI). The 
odds ratio is a measure that explains the association between an exposure and an 
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outcome (110) — for example, exposure to disease (IBS) and outcome (reduced 
conditioned pain modulation). We also calculated Hedge’s g effect size; this is a measure 
of the standardised mean difference between 2 groups(111). An effect size of > 0.8 is 
generally considered as a large effect size(112).  
The I² statistic and Cochran’s Q test were used to assess for study heterogeneity. The I² 
statistic describes the percentage of variation across studies that is due to a true 
heterogeneity, rather than chance, with values ranging from 0% to 100%. I2 values of 
25%, 50%, and 75% were considered low, moderate, and high(113). Cochran’s Q is 
distributed as per the chi-square statistic. We performed pre-specified subgroup 
analyses to ascertain whether there was effect modification by diagnostic criteria used 
or IBS sub-type. Tests were considered statistically significant if the p-value was < 0.05. 
We used a funnel plot to visually inspect for publication bias. Propriety software 
(Comprehensive Meta-Analysis, Biostat, New Jersey, USA, Version 2), was used to 




Search results  
The search generated 645 citations, of which 13 were relevant, and 12 met the inclusion 
criteria, see Figure 9. Of the 12 studies included, there were 248 patients and 216 
controls. All studies had a case-control design, see Table 5. 11 of the 12 studies were 











Records identified through database 
search 
638 















Studies excluded  
1 
• Wilder-Smith et al., 2004  
Full text articles assessed 
13 
  





Table 6: Summary of included studies. Abbreviations: F, females; HC, healthy controls; IBS, irritable bowel 
syndrome; IBS-C, irritable bowel syndrome-constipation predominant; IBS-D, irritable bowel syndrome-




















IBS, n = 20 
HC, n = 11 





Cold pressor test (2-
4C) 











IBS, n = 27 
HC, n = 21 




Cold pressor test 
(12C) 
Right hand 44 sec. 
Pain rating HC>IBS 





IBS, n = 46 
HC, n = 31 




Hot pressor test 
(46.5C) 
Contralateral hand 1 
min. 
Pain rating HC=IBS 





IBS, n = 20 
HC, n = 20 
Females only  
Heat stimulus 
Forearm 
Cold pressor test 
(12C) 
Contralateral hand 1 
min. 
Pain rating HC=IBS 





IBS, n = 14 
HC, n = 28 
Females only  
Heat stimulus 
Left hand 
Cold pressor test (8-
16C 0.1C) 
Right foot 30 sec. 
Pain rating HC>IBS 
Piché et al. 
(2013) (119) 
IBS-D IBS, n = 14 
HC, n = 14 




path of right 
sural nerve 
Cold pain (Ice pack -
12C) 
Left forearm 2 min. 
Pain rating HC=IBS 
Piché et al. 
(2011) (120) 
IBS-D IBS, n = 14 
HC, n = 14 
Females only  
Electrical 
stimulus 
Cold pain (Ice pack -
12C) 
Left forearm 2min. 




path of right 
sural nerve 
Piché et al. 
(2010) (121) 
IBS-D IBS, n = 11 
HC, n = 18 




path of left sural 
nerve 
Cold pressor test (4C) 
Right hand 2 min. 
Pain rating HC>IBS 





IBS, n = 12 
HC, n = 12 
Females only  
Rectal 
distention 
Cold pressor test (4C) 
Left foot 30 sec. 
Pain rating HC>IBS 
Wilder-Smith 





IBS, n = 40 
HC, n = 20 
Females only  
Rectal 
distension 
Cold pressor test (4C) 
Left foot 2 min. 
Pain rating HC>IBS 
Williams et 





IBS, n = 22 
HC, n = 16 
Females only  
Heat stimulus 
Right forearm 
Cold pressor test 
(12C 1C) 









IBS, n = 13, M = 6, 
F = 7 
HC, n = 11, M = 4, 
F= 7 















Diminished conditioned pain modulation in IBS 
Conditioned pain modulation in IBS populations versus healthy controls was more likely 
to be diminished with an odds ratio of 4.84 (95% CI 2.18-10.71, p<0.0001). There was a 
large standardised difference in mean between IBS and healthy controls with a hedges’ 
g effect size of 0.85 (95% CI 0.42 - 1.28, p<0.001)  (125). Significant heterogeneity 
between studies was noted (Q-test χ2 =52, p<0.001, I2 =78.8). Visual inspection of the 
Funnel plot did not provide evidence of publication bias, see figure 10. 
 
 
Figure 10: A Funnel plot of the included studies demonstrating symmetry which suggests that there is no 























































































































































































































































































































































































































Effect modification by diagnostic criteria used 
 
Of the 12 studies that met the inclusion criteria, nine studies used the Rome III definition 
and three studies used Rome II. The odds ratio of impaired conditioned pain modulation 
using the Rome II and III criteria was 3.44 (95% CI 1.76 - 6.70, p<0.0001) and 5.65 (95% 
CI 1.87 - 17.04, p=0.002) respectively, see figure 12. However, between groups analysis 
did not reveal a statistically significant difference; Q= 0.54, df= 1, p=0.46.  
 
Figure 12: Forest plot of the odds ratio of impaired Conditioned pain modulation according to different Rome 
IBS definition. The pooled odds ratio for Rome II, Rome III was 3.44 (95% CI 1.76 - 6.70, p<0.0001) and 
5.65 (95% CI 1.87 - 17.04, p-0.002) respectively. Abbreviations: CPM: Conditioned pain modulation, CI: 
confidence interval. 
 
Effect modification by IBS SUBTYPE 
Of the 12 studies that met the inclusion criteria, eight studies included pooled both 
subtypes of IBS patients into one group without reporting separate conditioned pain 
modulation outcome for each subtype, 1 study included only IBS-constipation (IBS-C) and 
three studies only IBS-diarrhoea (IBS-D) patients. The odds ratio of impaired conditioned 
pain modulation in IBS-D was 3.76 (95% CI 1.68 - 8.44, p=0.001), Q-test χ2 = 1.25, df =2, 
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p=0.54, I2 =0. Odds ratio based on the one study of IBS-C was 13.05 (95% CI 2.97 - 57.29, 
p=0.001), Q-test χ2 = 0, df =0, p=1, I2 =0.  For the studies with mixed populations of IBS, 
χ2 = 47.4, df =7, p<0.001, I2 =85.23.  There was no statistically significant difference when 
comparing the three groups of studies (IBS-D, IBS-C, and studies with mixed IBS 
populations), Q= 2.08, df=2, p=0.35. See figure 13.  
 
Figure 13: Forest plot of the odds ratio of Impaired Conditioned pain modulation in IBS subtypes. The pooled 
odds ratio for IBS-C was 13.04 (95% CI 2.97 - 57.29, p=0.001) and for IBS-D 3.76 (95% CI 1.68 - 8.44, 
p=0.001). Abbreviations: CPM: Conditioned pain modulation; CI: confidence interval; IBS-A, all mixed 
subtypes of IBS (i.e. not classified in the reporting paper); IBS-C, IBS with constipation predominance; IBS-




Study methodological quality assessment 
The methodological quality of the included studies is summarised in Table 6. A total bias 
assessment scale was agreed to range between 0-12, depending on individual criteria, 
with 0 indicating no bias. All the included studies scored between 2 to 5. None of the 




Table 7:  Study methodological scoring. 




































2 0 0 0 0 0 2 
Jarrett et al. 
(2016) 
(116) 
2 0 1 0 0 2 5 
Jarrett et al. 
(2014) 
(117) 
2 0 0 0 0 0 2 
King et al. 
(2009)(118) 
2 0 1 0 0 0 3 
Piché et al. 
(2013) 
(119) 
2 0 0 0 0 0 2 
Piché et al. 
(2011)(120) 
2 0 1 0 0 0 3 
Piché et al. 
(2010)(121) 
2 0 1 0 0 0 3 
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Song et al. 
(2006) 
(122) 
2 0 1 0 0 2 5 
Wilder-
Smith et al. 
(121) 
(2007)(123) 
2 0 1 0 0 0 3 
Williams et 
al.  (2013) 
(124) 
2 0 0 0 0 0 2 
Wong et al. 
(2016)(106) 
2 0 0 1 0 0 3 
 
Discussion 
Our meta-analysis illustrates that IBS patients are nearly five times more likely to have 
diminished conditioned pain modulation when compare to healthy controls. The 
increased likelihood is also associated with an important standardised difference in mean 
reflected by a large Hedge’s g effect size. Between groups comparisons, failed to show a 
significant difference between IBS subtypes or the Rome criteria used for diagnosis, 
although some interesting trends were noticed in this regard. Of note, King et al. yielded 
an odds ratio of impaired conditioned pain modulation that is many folds greater than 
any other study (118). However, this particular study was assigned the smallest relative 
weight in the random model used in this meta-analysis, making it unlikely that this has 
significantly skewed the overall results. Most studies (10/12) either used rigours criteria 
to exclude other painful conditions except IBS or reported separate data of patients with 
concomitant painful conditions; this enabled us to exclude such data from the meta-
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analysis. The latter makes it likely that the effect seen in this meta-analysis is related to 
IBS.  
These results have several important implications across the field, particularly 
concerning underlying pathophysiology of the disorder, as well as future clinical practice.  
The central defining characteristic of IBS is chronic abdominal pain, with a percentage of 
patients displaying heightened pain sensitivity to visceral stimuli, termed visceral 
hypersensitivity (126). Visceral hypersensitivity may arise, and be maintained, due to 
abnormalities at any level of the brain-gut axis, such as sensitisation of peripheral and 
central neurons  (127). Moreover, data from several functional brain imaging studies 
have also provided evidence for aberrant central pain processing in cortical and 
subcortical regions (102, 128, 129). Abnormal descending pain modulation is likely to 
adversely contribute to many of these mechanisms as it includes many of the constituent 
components of the brain-gut axis. Thus, there are three plausible explanations as to the 
deficiency in conditioned pain modulation that we have identified in IBS patients. Firstly, 
in this patient group, there is a true imbalance between descending inhibition and 
descending pain facilitation. Secondly, the ‘normal’ physiological descending inhibitory 
pain regulatory system is insufficient to dampen nociceptor recruitment at the level of 
the dorsal horn, where “gating” of visceral nociceptive afferent transmission occurs. 
Finally, a combination of dysregulation within descending pain modulatory pathways and 
established central sensitisation at the central nervous system may result in an overall 
impairment in conditioned pain modulation (130). This latter explanation is the most 
likely as the development of central sensitisation at the spinal dorsal-horn neurone level 
due to peripheral injury or inflammation may be a consequence of dysregulated 
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descending control from centres such as the rostral ventromedial medulla to the spinal 
dorsal horn (131). 
Several central nervous system regions are involved in the descending pain modulation, 
for instance, the insula, prefrontal anterior cingulate cortex, amygdala, hypothalamus, 
rostral ventromedial medulla and dorsal pons (132-134). The major neurotransmitters 
within the descending pathways are serotonin (5-HT), norepinephrine, and dopamine 
which regulate the excitability of dorsal horn neurons (32, 135, 136)- see figure 14. 
Notably, the above-mentioned brain regions and neurotransmitter pathways have 
important interactions with the autonomic nervous system (137, 138). Interventions that 
could reduce the descending excitatory effect, or enhance the descending inhibitory 
effect, may, therefore, be theoretically useful in the management of pain in IBS and such 




Figure 14: Descending pain modulation pathways identifying the main transmitter systems. Adapted from 
Benarroch(139). 
 
Current diagnostic classification of IBS is based upon symptoms in the absence of a 
demonstrable structural or biochemical abnormality (140). This has inevitably created an 
inherently heterogeneous group of patients. The management of pain in IBS is 
particularly problematic (141). Coupled with variation in clinical response and a high 
placebo response has represented significant challenges in the development of 
efficacious interventions  (142). A potential approach is personalised management based 
on individual features as advocated by the introduction of the multidimensional clinical 
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profile for the management of functional GI disorders (143).  Although recent studies 
have provided important insights into the pathophysiology of IBS, many of the methods 
used are often labour intensive, invasive, and expensive. In contrast, performing a 
conditioned pain modulation paradigms in IBS patients is straightforward, reproducible 
and inexpensive and requires only a minimal amount of specialist equipment (144). 
Recent evidence suggests that assessment of conditioned pain modulation may allow for 
the individualisation of pain treatments in other conditions of chronic pain; for example, 
Wilder-Smith et al. and Landau et al., showed that baseline conditioned pain modulation 
might predict postsurgical neuropathic pain (145-149).  
S. Sugimine et al. showed in a placebo-controlled study that the effect of pregabalin on 
conditioned pain modulation was strongly correlated with initial conditioned pain 
modulation (r = 0.73, p < 0.0001), the lower the initial conditioned pain modulation was, 
the more positive effect pregabalin had on conditioned pain modulation, oppositely, 
participant with initially high conditioned pain modulation may have a reduction in 
conditioned pain modulation after receiving pregabalin(150). Conditioned pain 
modulation has also been shown to predict analgesic  response to centrally acting 
medications targeting noradrenergic pathways in diabetic neuropathy(151). 
Interestingly, Niesters et all showed that Tapantadol (acts via opioid and noradrenergic 
pathways) could improve CPM in patients with diabetic neuropathy after 4 weeks of 
treatment(152).  
Neuromodulatory analgesic agents, such as tricyclic antidepressants and selective 
serotonin reuptake inhibitors (SSRI), have an established role in the management of IBS 
however, the number needed to treat remains relatively large (153-156). The exact 
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mode of action remains unclear but may be due to the interference with specialised 
brain networks involving emotional and cognitive processing of pain or by engaging 
descending pathways to alter pain transmission at the level of the dorsal horn of the 
spinal cord; both mechanisms can, in turn, alter conditioned pain modulation (157). 
Outcome studies investigating the relationship between conditioned pain modulation in 
IBS and response to neurotransmitters might offer an objective method to predict the 
efficacy of those medications and result in a more acceptable number needed to treat.  
There is a trend that patients diagnosed with Rome III criteria may have a more 
diminished conditioned pain modulation that those diagnosed with Rome II. Although 
the difference was not statistically significant, this may be due to a type 2 error, where 
only three studies used Rome III while nine studies used Rome II.  According to the Rome 
II criteria, abdominal pain or discomfort must be present for at least 12 weeks in the last 
12 months. In contrast, Rome III states that these symptoms must be present in the last 
three months with the start of symptoms of at least six months before the diagnosis. 
Notably, studies that have compared these criteria have shown that patients diagnosed 
using Rome III have significantly more severe abdominal pain and alteration in bowel 
habit than those diagnosed using Rome II (158). 
In contrast to the Rome III criteria, the Rome IV criteria have removed the term 
“discomfort” from the definition (159). While the prevailing reasons for this change were 
largely semantic, i.e. several languages do not have a word for discomfort, there are likely 
large variations in patients’ interpretation of this term (160). Coupled with changes in 
the temporal definition of abdominal pain, rising to weekly in Rome IV from 3 times 
monthly in Rome III, it is likely that this will lead to a reduction in the population 
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prevalence of IBS as the new diagnostic criteria will represent a more severe subgroup 
(161, 162). It is plausible to propose that a more severe IBS phenotype, characterised by 
greater pain, may have heightened deficiencies in conditioned pain modulation and thus 
may become a more salient pathophysiological feature of the disorder. This possibility 
requires confirmation in future studies.  
 
Limitations  
This study is not without limitations. Firstly, this meta-analysis was confined to study 
conditioned pain modulation in IBS and thus extrapolation to other functional 
gastrointestinal disorders, where visceral pain is a defining feature, is uncertain although 
similar deficiencies in conditioned pain modulation have been reported in patients with 
functional dyspepsia and functional abdominal pain (52, 54). Secondly, within the 
literature to date, there is a female bias in the recruited subjects (88%), and therefore 
generalizability to male patients is less certain. A previous meta-analysis reported that 
deficiencies in conditioned pain modulation in males is less than in females and may 
provide insights into the female preponderance in some types of IBS (163). The 
neurobiological basis of gender differences both in IBS and conditioned pain modulation 
is incompletely understood. It has been proposed that differences in pain sensitivity 
throughout the menstrual cycle may explain some of this variability (114). However, nine 
out of eleven studies included controlled for the stage of the menstrual cycle, thereby 
lessening the potential effect on our overall results. Thirdly, the identified studies were 
undertaken in tertiary care centres, so there is likely some inherent selection bias 
towards a more severe disease phenotype which potentially limits the external validity. 
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Fourthly, although, impaired conditioned pain modulation indicates a top-down 
dysregulation of pain control, it may not be able to differentiate between spinal, bulbar, 
cortical or emotional drivers of this dysregulation. Finally, we also demonstrated 
considerable heterogeneity between studies, particularly concerning differences in 
testing paradigms and outcome measures. However, Lewis et al. did not find that 
difference in the conditioning stimulus type, or test stimulus type significantly affects the 
study effect size (51). Nevertheless, our results show a clear association between IBS and 
impaired conditioned pain modulation, although no comment can be made on the 
direction of causality, which requires future longitudinal study.  
 
Concluding remarks  
In conclusion, this meta-analysis supports the hypothesis that conditioned pain 
modulation is diminished in IBS. This deficit is likely due to a combination of a 
dysregulated descending pain modulation and central sensitisation. In future, 
conditioned pain modulation paradigms could be used to improve homogeneity in 
clinical trials, although the international consensus is needed on the specific parameters 
of such paradigms such as the use of rectal distention vs somatic pain, the type of 
conditioning stimulus and controlling for possible confounding factors (164). An 
interesting potential of this technique may be the personalisation of neuromodulatory 






Chapter 4  
The Effect of Experimentally Induced Oesophageal 
Hypersensitivity on Conditioned Pain Modulation 
 
Introduction 
Pain is a common experience that drives behaviour and plays an important role in 
survival. Pain experience may differ from individual to individual; however, depending 
on the circumstances, such experience may also differ within the same individual. The 
difference is sometimes quite remarkable; for example, it has been reported that soldiers 
may report little pain to gun-shot wounds during the battle(38).     Such variability in pain 
experience is possible due to a complex pain control system that intervenes at multiple 
levels; from pain conduction at the periphery, transmission to the central nervous 
system, to the processing of such stimuli at cortical levels.  
 
One of the mechanisms of interest in this study is the descending inhibition of pain that 
may account for some on the variation in pain experience and may be used as a gateway 
to therapeutic pain regulation in the future. Descending inhibition refers to the ability of 
central nervous system structures (such as brainstem, limbic system, cortical regions) to 




One way of assessing descending inhibition is by measuring the Conditioned Pain 
Modulation (CPM). CPM refers to the endogenous pain inhibition of a specific stimulus 
when a second pain stimulus is applied simultaneously but in another region of the body. 
It is evaluated by assessing participant’s pain threshold to a specific stimulus (test 
stimulus), then reassessing it after applying a second painful stimulus, also called 
conditioning stimulus. Following the principle that ‘’pain inhibits pain’’. CPM was formally 
known as Diffuse Noxious Inhibitory Control (DNIC) described by Le Bars, Dickenson and 
colleagues (47). DNIC is a specific term that refers to a brainstem mediated mechanism; 
thus, Conditioned Pain Modulation was adopted as an alternative term to incorporate 
the psychophysiological factors important in shaping this type of pain control in 
humans(48).    
 
In healthy humans, there is a significant increase in pain threshold to the test stimulus 
after applying a second conditioning stimulus(49). Conditioned pain inhibition is thought 
to be mediated via Diffuse Noxious Inhibitory Control system. In rats, DNIC is thought to 
be mediated via neurones in the subnucleus reticularis dorsalis (SRD)(50). However, 
human studies suggest the involvement of other nuclei such as the Periaqueductal grey 
and structures that allow for interactions with higher structures such as the autonomic 
nervous system, emotional centres, past experience and other factors (51, 165, 166).  
 
CPM is reduced (i.e. reduction in pain threshold to the test stimulus after application of 
the conditioning stimulus is less pronounced) in a variety of chronic pain conditions such 
as Functional Abdominal Pain, Irritable Bowel Syndrome, Functional Dyspepsia, etc. (52-
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54). This reduction in CPM has a large effect size of in various types of painful conditions 
as suggested by a meta-analysis (51).  
 
Descending pain modulation dysregulation may play a key role in visceral pain 
hypersensitivity where there is an exaggerated response to a potentially painful stimulus 
or sometimes without an obvious stimulus. Pain hypersensitivity is thought to take place 
at one or more levels, such as:  
• Peripheral: enhanced transduction of painful signals as seen during local injury or 
inflammation (peripheral sensitisation) 
• Central: at the level of the dorsal horn of the spinal cord where pain signals are 
integrated and amplified before being projected to higher structures (central 
sensitisation) 
• Cortical level: during the perception (interpretation) phase  
Current literature of CPM in visceral pain cannot fully explain the relationship between 
visceral pain hypersensitivity and CPM for several reasons:   
• In chronic visceral pain conditions, is not possible to assess the baseline CPM 
before the condition started; thus, it is difficult to say whether the reduction in 
CPM preceded visceral pain or it is a consequence of it 
• Unlike acute painful conditions, in chronic visceral pain conditions such as 
functional gastrointestinal disorders, the painful condition does not completely 
resolve with time, thus, it is not possible to assess CPM in those patients after the 
painful condition has resolved. 
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• Unlike other types of pain, where the insult stimulus is well-known and 
potentially treatable, the insult stimulus in visceral pain is often vague and non-
targetable 
For all the above reasons, a better human experimental model is needed to investigate 
the link between CPM and visceral hypersensitivity.  
 
Our group has pioneered a human model to investigate acid-induced experimental 
oesophageal hypersensitivity. The model allows the study of central sensitisation in 
healthy humans. Below is a basic description of the model:  
 
Human Model of acid-induced oesophageal hypersensitivity 
 
 
Most participants (approximately 70%, Sharma 2012) will drop their pain threshold by > 
6mA as a consequence of developing central sensitisation 
Participant will rest for 30 min to allow for sensitisation to take place, after that pain 
threshold is retested 
Pain threshold is measured at baseline, then 0.15 mmol of HCL is infused for 30 min 
(8ml/min) just above the level of the lower oesophageal sphincter 
At the distal end of the catheter, there is a perfusion port while 15cm above that level 
there is a stimulating electrode used for measuring electrical pain threshold 
Nasal catheter is passed in the oesophagus with the tip resting 2 cm above the lower 
oesophageal sphincter 





This model has been validated against saline infusion and has been repeatedly used and 
validated by our group and others (68, 167-169). The stimulation electrode is placed 15 
cm proximal to the acid infusion port to avoid testing the pain threshold at the inflamed 
section of the oesophagus, thus testing central sensitisation rather than peripheral 
sensitisation. Previous studies confirmed the absence of pH changes at the level of 
stimulation electrode (168).  This model also allows for the collection of autonomic 
variables throughout the experiment using ECG signals.  Our group has shown a 
significant association between the development of visceral hypersensitivity and the 
reduction in parasympathetic tone (168) such that those who reduce their 
parasympathetic tone the most during acid infusion also sensitise the most; thus, the 
proposed study provides an exploratory data regarding a possible association between 
CPM and parasympathetic tone.  
 
In this model, approximately 70% of participants sensitise (drop their pain threshold by 
> 6mA) to the established dose and period of acid-infusion (168). 
 
CPM response may differ depending on gender as it is less pronounced in females (51). 
It has also been shown that CPM depends on the phase of the menstrual cycle (170). We 
accounted for this by studying females only, in their follicular phase of the menstrual 
cycle. The choice to study females is also because of the predominance of this gender in 






Figure 15:  A schematic representation of the oesophageal pain hypersensitivity model. From left to right: - 
A- a catheter is placed in the oesophagus which has a proximal pH probe and silver bipolar electrical 
stimulation electrodes to measure oesophageal pain sensitivity and a distal pH probe & infusion port. B – 
Subjects are randomised to receive either saline or acid infusion. As expected, when saline was infused, 
pH remained stable in the proximal and distal oesophagus, whereas there is a demonstrable drop in pH in 
the distal but not the proximal oesophagus during acid. C- Following saline infusion, pain thresholds in the 
proximal oesophagus -which has not been exposed to acid- show decreased pain sensitivity, i.e. increase 
in pain thresholds over time (green-shaded area) due to habituation, but following acid infusion, there is 
increased pain sensitivity, i.e. decrease in pain thresholds over time (red-shaded area) due to central 




• Baseline CPM can predict the development of experimentally induced 

















If CPM is associated with visceral hypersensitivity, then: 
• It can be used as a surrogate maker when evaluating potential treatments for 
visceral hypersensitivity 
• In future studies, therapeutic interventions may target CPM pathways to treat 
visceral hypersensitivity 
Main aims:  
• To investigate the relationship between CPM and experimental oesophageal pain 
hypersensitivity  
• To investigate if baseline CPM can predict the development of experimental 
oesophageal hypersensitivity  
Primary outcome measure 
CPM before and after acid infusion. CPM is calculated as the percentage change in ‘test 
stimulus’ pain threshold (PT) before and during the conditioning stimulus.  
Secondary outcome measure  
Autonomic measures, including Cardiac Vagal Tone measured for 5 minutes, at baseline 








Inclusion criteria  
• Women aged 18-65 years 
• No chronic pain conditions, including Irritable Bowel Syndrome, fibromyalgia, 
migraine, and other pain conditions  
• Not on any regular medications  
• No history of Gastroesophageal Reflux Disease (heartburn less than twice per 
week) 
• No heart conditions such as arrhythmias   
Exclusion criteria 
• Not meeting all inclusion criteria  
• Not able to give informed consent (poor command of English language)  
• Pregnancy  
• Cold-induced problems such as: 
• Raynauds disease  
• Injuries or skin conditions on the foot  
•  Cold-induced skin disorders such as Cold-induced urticaria and similar 
conditions  
•   Known intolerances to cold temperature for other reasons not mentioned 




We controlled for: 
• Gender: we recruited women only  
• Menstrual cycle phase: all participants were studied during the follicular phase  
• Alcohol consumption, caffeine; restricted 24 hours before the study 
• We collected information for co-variate analysis such as age, gender, BMI, other 
medical conditions, rigorous exercise, sleep deprivation and psychological factors 
and anxiety using validated questionnaires  
• We standardised the investigator-participant interaction by keeping verbal 
















High-resolution oesophageal manometry  
To define the anatomical landmarks of the oesophagus (i.e. position of the lower 
oesophageal sphincter, if the recruited subject has not been studied before using this 
model), then high-resolution oesophageal manometry (HRM) was performed using 
End of the study 
Second CPM measurement (left foot in ice-water)
Pain threshold measurements 
30 min rest to allow for sensitisation 
Oesophageal acid infusion for 30 min 
10 min rest 
Baseline CPM measurement (left foot in ice-water)
Baseline Pain threshold measurements (oesophageal electrode) 
5 min of autonomic baseline 
Oesophageal intubation with a special catheter ; through the nose 
High-resolution manometry to locate the lower oesophageal sphincter (not a full 
test) 
HAD, State and Trait questionnaires 
Signing the informed consent form 
Screening and going through inclusion and exclusion criteria 
Discussing the participant information sheet  
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ManoScan 360™ High-Resolution Manometry system from Sierra Scientific . A specialised 
HRM catheter sheathed in a single-use sleeve was inserted through the nostril into the 
oesophagus until the distal end of the catheter is resting in the proximal stomach. The 
catheter is then taped to the nose. Lower oesophageal sphincter (LOS) position, in terms 
of cm from the nostril, was recorded and used to guide insertion of naso-oesophageal 
catheters in the next phases of the study. Manometry is a routine diagnostic test. 
 
Autonomic nervous system measurements 
At baseline, and continuously after that, measurement of the parasympathetic tone 
using cardiac vagal tone was made using the non-invasive Neuroscope system (172).  
 
Acid infusion and pain tolerance measurements   
Oesophageal intubation  
A specialised catheter was inserted through the nose into the oesophagus (3 mm 
diameter catheter, Unisensor AG, Ch-8544 Attikon, Switzerland). The catheter has a 
distal infusion port (5cm from the tip) and a proximal stimulation electrode to test pain 
thresholds (16 cm proximal to the tip). The tip of the catheter will be placed 2 cm above 




Pain tolerance threshold testing  
Pain tolerance threshold (PTT) in this protocol is defined as the level of pain when 
participants report that they cannot tolerate any further increase (Visual analogue scale 
or VAS of 7 out of 10).  
Electrodes were connected to an electrical stimulator and stimuli are delivered at a 
frequency of 0.5 Hz, using square wave pulses (0.5 s duration), at intensities varying 
between 0 and 90 mA. The intensity of stimulation was increased incrementally by 2 mA 
until reaching the pain threshold.  The electrical stimulation was immediately stopped 
when PTT was reached. 
Pain tolerance threshold was measured at baseline (T0) and, at 60 minutes (T60) after 
starting the distal oesophageal acid infusion. The same technique was used to measure 
pain threshold to assess CPM.  
 
 Oesophageal acid infusion  
Using the distal port on the oesophageal catheter, we infused 0.15 molar hydrochloric 
acid (T10-40) (medical grad product, used in practice for IV infusion) using an intravenous 
pump with a rate of 8 ml per minute for 30 minutes.  
 
CPM testing  
CPM was calculated as the percentage change in PTT before and during the conditioning 
stimulus. Example: If baseline PTT=100mA, PTT during the cold condition stimulus is 
120mA, then CPM= +20%. 
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After obtaining oesophageal electric PTT, we applied conditioning stimulus by placing the 
left foot in cold water that kept at 2-4 degree Celsius (temperature is kept within the 
interval by adding ice cubes). Then we tested oesophageal PTT as detailed in the above 
section while the conditioning stimulus is applied throughout the pain tolerance testing.  
Cold-stimulus is known to be effective in eliciting a CPM response(51). Traditionally, the 
conditioning stimulus is applied to a heterotopic (on the other side) place from the test 
stimulus; thus, the position on the feet was chosen to avoid applying both stimuli to the 



























Statistical considerations  
Statistical analysis  
We used partial correlation method using SPSS 25 IBM. We statistically corrected for age, 
height and weight.  
 Sample size calculation 
Using a regression model with an estimated effect size of CPM in chronic pain conditions 
to be 0.78 (adopted from a meta-analysis (51), 16 participants must complete the study 
to have 80% power and 0.05 alfa level.  
 
Ethical approvals  
This study was approved by Queen Mary, University of London Ethics committee. 




Relationship between baseline CPM and sensitisation  
 
There was a strong and significant correlation between baseline CPM and the degree of 
sensitisation, r=0.695, p=0.008. Delta PTT below refers to the post-acid infusion pain 
threshold as a percentage from baseline pain threshold. For example, participants who 
reduce their PTT by 20 percent, will have a Delta PT of 80%, while participants who 
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reduce their PTT by 10 percent have a Delta PT of 90%.  Thus, more sensitisation takes 
place, the lower Delta-PT will be.  
 




Table 8 Partial correlation between baselines conditioned pain modulation (CPM) and delta pain threshold 
adjusted for age, height and weight   
Control Variables Baseline 
CPM 
Age & Height (cm) & 
Weight (kg) 









Relationship between change in CPM and sensitisation  
 
There was an inverse correlation between the direction of CPM and sensitisation, r= -
0.558, p= 0.047. The higher degree of sensitisation correlated with a larger increase in 
CPM from baseline. This may suggest that participants who sensitised the most 
attempted to increase their CPM the most. However, these participants had a low CPM 
at baseline.  
 








Table 9: Correlation between change in CPM and change in pain threshold after oesophageal acid infusion 
adjusted for age, height and weight. df: degree of freedom.   
Control Variables Delta PT 
Age & Height (cm) & Weight (kg) Delta CPM Correlation -.558 
















Relationship between baseline CPM and baseline cardiac vagal tone  
 
We could not detect a significant correlation between baseline cardiac vagal tone and 
baseline conditioned pain modulation, r= -0.214, p=0.483.  
 
Table 10: Partial correlation between baseline cardiac vagal tone and baseline conditioned pain modulation. 
df: degree of freedom.   
Control Variables Baseline 
CPM 


















Other data  
For a summary of other collected data, please refer to the tables below. No statistics 
were performed to avoid multiple testing.  
 
Table 11: Absolute values of autonomic variables during the interventions   





HR baseline HR acid 
infusion 
HR rest 
Total Mean 11.1818 12.3465 13.6312 71.818 69.065 67.506 
Std. 
Deviation 
5.52676 4.60099 5.90688 11.8310 8.8992 8.7209 




Table 12: Demographic data of participants and CPM  













4.897 7.7476 24.71599 
Skewness 1.29
3 






All participant had a normal HAD score of less than 7.  
Discussion 
Functional gastrointestinal disorders are grouped and diagnosed according to clinical 
criteria rather than physiological and pathological criteria. This is clinically useful, mainly 
for prognostic reasons and to exclude sinister diseases. However, the clinical 
classification will inevitably create an umbrella term that groups several distinct 
pathological mechanisms under the same disease heading. This is particularly 
problematical in research. For example, if a specific intervention is effective against a 
subtype of a functional disorder with anxiety as the main feature, then it may be less 
effective in patients with similar symptoms that are driven by enteric nervous system 
dysfunction. Detecting an intervention with a moderate effect size in heterogeneous 
groups is challenging and will need a very large number of participants. For this, we are 
likely to miss reasonably effective intervention when tested based on symptoms only. 
One of the theoretical mechanisms in functional gastrointestinal disorders with pain as 
the main feature is a dysregulated top-down control (see the previous chapter). This 
study clearly shows that the status of baseline top-down control measured by 
Conditioned Pain modulation is a strong predictor of pain sensitisation. Those with 
relatively effective conditioned pain modulation are less likely to sensitise. On the other 
hand, those who sensitise the most, increase their CPM in percentage terms the most 
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from baseline. Although the percentage change is more when compared to those with 
less sensitisation, they have a lower baseline to start with.  
The correlation between baseline CPM and sensitisation is strong and significant, 
suggesting a relevant underlying mechanism. CPM is a surrogate marker of top-down 
control. However, it cannot pinpoint the level of dysregulation. CPM is influenced by 
several structures, spinal, bulbar, autonomic and cortical structures. Given the broad 
range of control, it is very challenging to pinpoint the dysfunctional part of the chain. 
However, interventions along the chain are likely to be effective, especially at the top 
level of the chain, such as cortical structures involved in the processing of pain.  
 
CPM may be a rudimentary way of assessing top-down pain control. However, it may 
predict participant likely to develop pain hypersensitivity when exposed to a sensitising 
stimulus. Our study clearly shows this in experimental settings. Wilder-Smith et al. and 
Landau et al. showed that baseline conditioned pain modulation might predict 
postsurgical neuropathic pain (149, 173). Those conclusions are in line with our findings.  
The foreseeable benefits of incorporating CPM in research and perhaps clinical practice 
can be summarised as below.  
First, CPM can be used to monitor treatment progress in patients with chronic painful 
conditions, especially if a pharmaceutical agent is used that is known to target 
descending inhibition.  
Second, it can also be used in research to reduce heterogeneity and thus to reduce the 








This was a study undertaken in a stringent laboratory setting that is rarely met in the real 
clinical world. This study indicates that CMP is a reasonable predictor of developing pain 
hypersensitivity in healthy volunteers; however, this conclusion will need further testing 
in clinical settings.  Another limitation is that we recruited female participants only, thus 
extrapolation to male populations may require further testing.   
 
In conclusion, conditioned pain modulation at baseline is a strong predictor of 
developing experimental pain hypersensitivity in healthy volunteers. Conditioned pain 
modulation may be a useful tool to predict the efficacy of therapeutic interventions 
targeting descending inhibitory pathways. Conditioned pain modulation may also be a 









Chapter 5:  
The Effect of Transcutaneous Vagal Nerve Stimulation on Pain- 




We have previously published an extensive review regarding the clinical uses of Vagal 
nerve stimulation (174). Vagal nerve stimulation has been used in various pain conditions 
with some degree of success in experimental studies. My main interest is using vagal 
nerve stimulation for the central modulation of pain, more specifically, oesophageal pain 
hypersensitivity. However, oesophageal pain hypersensitivity is a novel application with 
no publications regarding the use of vagal nerve stimulation in this condition.  For this 
reason, we had to widen our literature search to all types of pain.  To understand the 
degree of evidence of this intervention, we conducted a systematic review of the 
literature and a meta-analysis of the effect of non-invasive vagal nerve stimulation on 











• Prospective randomised controlled studies investigation non-invasive Vagus 
nerve stimulation in humans in pain conditions   




The study was conducted according to PRISMA guidelines and registered on PROSPERO 
web site. Two researchers independently searched Pub Med and Web of science. Those 
two researchers were students who worked under my supervision to conduct this 
project. They had training in principles of evidence-based medicine, and literature 
search.  Keywords were agreed to be: vagus nerve stimulation, Or Vagus AND pain. The 
search was restricted to human studies only. We included all articles published prior to 
31.04 2018. There was no restriction on language. The abstracts were screened, full 
papers were screened if met inclusion criteria.  
 
Data extraction 
Using a designed Excel Spreadsheet (Excel 2016, Microsoft, Redmond, USA), Data were 
extracted independently by two investigators. This data included study identifiers, 




Study methodology quality assessment 
 
A checklist was designed to assess the risk of bias in 6 categories. The risk for each 
category was set as low (0 points), moderate (1 point) or high (2 points). The categories 
were:1) blinding of assessors  (high risk if not blinded or not clearly stated) 2) use of 
internationally accepted criteria for underlying clinical condition (high risk if not stated, 
moderated risk if not internationally validated) 3) matching of treatment and control 
groups concerning age  (low risk if <10%, moderate if 10-20% and high >20%) 4)  
matching of treatment and control group concerning gender (low risk if <10%, moderate 
if 10-20% and high >20%) 5) the exclusion of depressive disorders as a known confounder 
to pain (high risk if not mentioned, moderated risk if mentioned and measured and low 
risk if excluded or adjusted for) 6) control for other known confounders such as 
menstrual cycle phase, the time of day of assessment, caffeine or alcohol intake, 
concomitant medication use (pain-killers), stress or anxiety  (the high risk was considered 
in case of control for one or fewer confounders, moderate risk was assumed when at 
least two confounders were controlled, and the low risk was attributed to control for 





Due to the expected heterogeneity between the included studies, we used a random-
effects model using Der Simonian-Lard weights. We used the Hedges g with 95% 
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confidence intervals to measure effect sizes (175, 176). An effect size of 0.2 is considered 
small, while 0.5 is medium and 0.8 is large. The effect size is a measure used to estimate 
the difference between the treatment and the control groups regarding the pain-related 
effect of vagal nerve stimulation 
The Higgins I2 test is used to determine heterogeneity. It ranges between 0% to 100% 
where 25%, 50%, and 75% indicate low, medium and high statistical heterogeneity 
respectively (177). Publication bias was assessed by visual analysis of the funnel plot. 
Comprehensive Meta-analysis, Biostat, New Jersy, USA, Version 2 software was used to 















Search results:  
Search results are summarised in Figure 20. 
 








1060 studies broadly 
screened 
1045 studies excluded 
after evaluation of 
title/abstract 
15 papers retrieved 
for the full-text 
assessment 
6 studies excluded 
because: 
5 were not controlled 
1 post hoc analysis  
 





Characteristics of the included studies  
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Bias assessment  
Methodological quality assessment is summarised in table 13. Visual analysis of the 
funnel plot did not suggest publication bias, see figure 21.  























Busch,2013 0 0 0 0 0 1 1 
Frokjaer,2016 0 0 0 0 2 0 2 
Goadsby,2018 0 0 0 0 2 2 4 
Kovacik,2017 0 0 0 0 2 1 3 
Laqua,2014 2 0 0 0 2 2 6 
Napadaw,2012 2 0 0 0 2 1 5 
Silberstein,2016 
ACT1 
0 0 0 0 2 2 4 
Silberstein,2016 
EVENT 
0 0 0 0 2 2 4 









Figure 21: Funnel plot of the included studies, the visual inspection does not indicate a significant publication 
bias  
Heterogeneity of included studies  
There was a large heterogeneity in the included studies; Q-value 134.08, I 
squared=83.59, p-value < 0,001 
The overall effect of vagal nerve stimulation on pain  
Non- invasive vagal nerve stimulation had a small but significant effect on pain; Hedges 




















































































































































































Statistics for each study
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Silberstein et al; ,2016  ACT one
Mean PI at 15 min  Ech+Cch
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Silberstein et al; ,2016 EVENT
Mean change in the number of headache days/ week








Usichenko T et al, 2017
Heat pain thresholds




























Effect modification by type of pain 
Vagal nerve stimulation appeared to have a significant effect on somatic and visceral pain 
but not on headache. The overall Hedges’ g of 0,564 (0,173-0,955; p= 0,005) was 
observed in visceral pain whereas the effect size of somatic pain was 0,328 (0,033-0,623; 
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Our study shows that there is a small but statically significant effect of non-invasive vagal 
nerve stimulation on pain. It is no surprise that the included studies had significant 
heterogeneity. Studies differed in conditions being treated, location of vagal nerve 
stimulation, stimulation parameters, and primary endpoints. Despite that, there is a 
modest but significant effect size when compared to sham.  
Subgroup analysis showed that vagal nerve stimulation reduces visceral pain and somatic 
pain but not headache. These data are based on a few studies with marked 
heterogeneity. For example, the data for visceral pain is based on one study only(178). 
In contrast, there is marked heterogeneity in studies addressing pain in chronic 
headache. This review included one study addressing chronic migraine and two other 
studies on cluster headache. Cluster headache can be further subdivided to chronic 
cluster and episodic cluster headache.  
With regards to somatic pain, the overall effect size was statistically significant in favour 
of vagal nerve stimulation, but Hedges’ g of individual studies varied depending on pain 
modalities. The small number of studies did not allow for further subgroup analysis of 
mechanical and thermal modalities separately; instead, we could only extrapolate on the 
overall effect size on somatic pain. Although the “mechanical” pain modalities were 
found to be more significantly reduced by vagal nerve stimulation, tonic pain models 
showed promising results with regards to both mechanical and heat paradigms. These 
findings suggest a role of a central mechanism of action of vagal nerve stimulation as the 
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tonic pain paradigms test temporal summation, which is central nervous system-specific 
(179). 
The included studies used various device locations. Frokjaer et al., applied the stimulator 
exclusively on the cymba conchae, whereas in other studies the device was placed on 
the cavity conchae, tragus or dorsal and ventral aspects of the ear. These areas could be 
additionally supplied with the great auricular and trigeminal nerves that may reinforce 
the vagal nerve stimulation via connections to the spinal trigeminal nucleus (3, 180).  
 
Stimulation of the tragus, dorsal and ventral aspects of the ear tended to show positive 
results, while studies that used cervical stimulation tended to be negative. These 
observations must be accepted with caution because the effect size may reflect several 
factors such as different disease populations, duration of stimulation, parameters of 
stimulation and many other factors.  
 
Laqua et al. and Usichenko et al. studies did not show an overall difference between 
active and sham intervention with regards to experimentally induced electrical and heat 
pain, respectively (5, 6). However, the detailed subgroup analysis of participants with 
vagal nerve stimulation suggested a decreased pain threshold indicating a pro-
nociceptive effect. Those results could be potentially explained either a type one error 




The exact mechanics are unknown. Kovacic et al., (8), demonstrated a hypoalgesic effect 
of percutaneous electric nerve field stimulation on patients with functional abdominal 
pain. The authors postulate that this effect might be driven via stimulation of brainstem 
nuclei involved in pain pathways, such as the Nucleus of the Solitary Tract (NTS). This 
stimulation is likely to be anatomically medicated via vagal nerve stimulation (VNS). The 
other studies also showed a similar antinociceptive effect of VNS on various types of pain.  
The effect is seemingly independent of the stimulation parameters. To our knowledge, 
no human study has investigated precise parameters to elicit a specific response but 
rather used known parameters to avoid habituation and remain safe.  
 
Despite considerable progress in our understanding of the neurobiology of vagal 
afferents, a mechanistic appreciation of how VNS exerts a seemingly diverse beneficial 
effect remains lacking. However, we would propose two factors that may explain this. 
Firstly, the possibility of publication bias. This is less likely for one reason; there are a 
plethora of possible combinations of stimulation parameters such as frequency, 
wavelength, wave morphology, current intensity, shape of the electrodes, size of the 
electrodes, individual differences in skin resistance, proximity of nerve afferents to the 
electrodes, duration of stimulation, time of the day of stimulation and finally anatomical 
variations in skin innervation. To find a specific stimulus, the proportion of negative 
studies to positive studies must be large. Thus, even with large publication bias, negative 
studies should considerably outnumber positive ones, which is not what we see. 
Secondly, it is plausible to suggest that the effect of VNS is non-specific. The hypoalgesic 
effect may be driven via sending nonspecific signals at the level of the brainstem. These 
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signals will have a ''competing for effect'' with incoming pain stimuli or perhaps triggering 
a nonspecific reflex that activates descending pain inhibition or even results in a 
nonspecific release of inhibitory neurotransmitters. The effect is therefore independent 
of the stimulation parameters or perhaps type of the stimulation as long as such stimuli 
reach specific brainstem nuclei involved in pain pathways. If this hypothesis is sound, the 
hypoalgesic effect could be induced by the stimulation of any of the cranial nerves. For 
example, Kovacic et al used an enlarged auricular field that encompasses areas supplied 
the great auricular and trigeminal nerves that may, in turn, stimulate the vagal nerve via 
communications with the spinal trigeminal nucleus(8). For anatomical considerations, 
the vagus nerve is perhaps one of the best candidates due to its extensive network. If 
this is the case, then we can argue that the shape of the electrode, exact location or 
parameters, etc. are less relevant if they avoid habituation and remain safe.  
 
The exact neurobiology of how a competing stimulus prevents incoming pain signals at 
the level of the brainstem remains to be elicited. In Melzack and Wall’s ‘’gate-control 
theory of pain’', competing (non-noxious) stimulus can inhibit noxious stimulus at the 
level of the spinal cord (41). Our hypothesis shares many aspects of this theory, with the 
evident difference that the level of inhibition is at the level of the brainstem rather than 
the spinal cord. It is evident that this conceptual hypothesis needs significant tuning and 
extensive testing.  
 
In summary, this literature review and meta-analysis suggests that vagal nerve 
stimulation has an anti-nociceptive property.  While the effect size was modest but 
135 
 
remained statistically significant. There is important heterogeneity in those included 
studies which may limit subgroup analysis at this stage.  
 
In conclusion, there is enough literature data in favour of the anti-nociceptive effect of 
noninvasive vagal nerve stimulation that warrant further investigations and clinical trial 













Chapter 6  
Effect of Transcutaneous Vagal Nerve Stimulation on Reversing 




Oesophageal pain is a major global cause of disability, healthcare-seeking and reduction 
in quality of life (181). Chronic oesophageal pain is a symptomatic feature of disorders 
such as erosive oesophagitis, non-erosive reflux disease and non-cardiac chest pain. The 
latter has been estimated to account for approximately 700,000 consultations in the 
accident, and emergency departments with care costs to the National Health Service 
estimated to be in the order of £83 million per annum. Patients often display heightened 
sensitivity to intra-oesophageal stimuli, which is referred to as oesophageal pain 
hypersensitivity (182, 183). However, the experience of oesophageal pain is highly 
individual with a multitude of factors including physiological and psychological factors 
proposed to account for this variability (172).  
 
Amongst the physiological factors, autonomic nervous system (ANS) plays an important 
role. The ANS is a bidirectional, hierarchically controlled brain-body nexus that integrates 
the external environment with the internal milieu. The ANS has been postulated to play 
a pivotal role in the modulation of pain through its multiple interactions that occur at the 
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level of the periphery, spinal cord, brainstem, and forebrain (184). The ANS has two 
broadly antithetic branches, the parasympathetic nervous system (PNS) and the 
sympathetic nervous system (SNS). The primary neural substrate of the PNS is the vagus 
nerve.  
 
Previously, we have sought to determine the role of ANS in modulating oesophageal pain 
hypersensitivity using a safe, well-validated clinical model of oesophageal pain (40), 
where participants were randomised to receive saline or acid infusion in the lower 
(distal) oesophagus. Following acid infusion into the distal oesophagus, pain thresholds 
to electrical stimulation are reduced in both the exposed (distal) and the (upper 
(proximal)) non-acid exposed oesophagus, the latter most likely as sequelae of central 
sensitization.  
Work from our group has demonstrated that during distal oesophageal acidification, 
there is a rise in SNS tone and a fall in PNS tone (167). Interestingly, we have also 
demonstrated that participants who decreased their PNS tone the most developed a 
heightened degree of oesophageal pain hypersensitivity (168). Despite progress in 
identifying the mechanisms that account for development and maintenance of the 
oesophageal pain hypersensitivity, translation into efficacious drug treatments has 
remained limited, notwithstanding concerns regarding safety and side effects (185). 
Therefore, it is not surprising that several psychological and alternative/complementary 
interventions, such as cognitive behavioural therapy and yoga, have been employed in 
the management of oesophageal pain syndromes (186).  
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A common feature of these interventions is the conscious control of breathing frequency 
and depth. Deep breathing has been proffered as a method of inducing analgesia, 
possibly through increasing PNS tone (187). These data and ours provided a rationale for 
the suggestion that the PNS may have analgesic properties in the oesophagus. We have 
recently examined this possibility using the oesophageal pain hypersensitivity model 
where participants undertook either, deep breathing to physiologically increase PNS 
tone or normal (sham) breathing during oesophageal acidification. Deep breathing 
significantly increased cardiac vagal tone (figure 24 panel A) and prevented the 
development of oesophageal pain sensitivity (188), (figure 24 panel B). It has been 
proposed by our group that other methods of increasing PNS tone, for instance 
electrically, have a similar effect (submitted, QMERC2014/5).                                                                                                                        
Electrical vagal nerve stimulation (VNS) was first used in humans in 1988 and is an 
efficacious treatment for drug-resistant epilepsy (189). Traditional VNS is undertaken in 
a procedure where a bipolar helical electrode is placed around the cervical vagal nerve, 
which is connected to a pulse generator placed in a subcutaneous pocket in the chest, 
not dissimilar to a cardiac pacemaker, (figure 25 panel A). However, this method of VNS 
necessitates surgical implantation with its attendant risks and complications (190). 
Recently, an external transcutaneous VNS (t-VNS) system, consisting of an earplug-like 
electrode to interface with the concha of the outer ear and a handheld battery-powered 
electrical stimulator, has become commercially available (NEMOS system(CE marked)), 
(figure 25 panel B). The auricular branch of the vagus nerve innervates the concha of the 
ear and is located directly under the skin, making it a suitable target for transcutaneous 
stimulation. t-VNS has been demonstrated to be safe, well-tolerated and has a high 
degree of user-friendliness. A preliminary study has reported that t-VNS reduces 
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sensitivity to heat pain in healthy volunteers (7). Furthermore, recent studies have 
demonstrated that t-VNS patterns of brain activation, as determined by functional 
magnetic resonance imaging, were similar to those evoked by traditional VNS (191). 
Thus, VNS per se represents an attractive proposition for investigating the role of the 
PNS in oesophageal pain and t-VNS specifically, a viable, safe and acceptable technology 
for achieving this. 
 
 
We have recently examined the possibility of using the proposed tVNS device to prevent 
the development of acid-induced oesophageal hypersensitivity in our human model 
described above, where participants undertook either active tVNS, to increase PNS tone 
or sham tVNS during oesophageal acidification. tVNS significantly increased cardiac vagal 
tone and prevented the development of oesophageal pain sensitivity (manuscript 
Figure 24: A- The effect of sham breathing (shaded black) and deep breathing (unshaded) on the cardiac 
vagal tone (PNS tone) indicating that deep breathing increases vagal tone (p<0.0001). 
B- The effect of sham breathing, deep breathing and deep breathing + atropine on change in pain 
thresholds. Mixed effects regression modelling showed a coefficient of effect for deep breathing of 9.94 
(95% CI 8.3-11.6, p= 0.0001). Atropine blocked the analgesic effect of deep breathing. Adapted from Botha 
et all, Gut 2014.  
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submitted, QMUL Ethics approval number QMERC2014/5) (figure 26). Although the 
latter study shows that tVNS prevents the development of oesophageal hypersensitivity 
when used simultaneously with acid infusion, in many patients, acid-induced 
oesophageal hypersensitivity is due to Gastro-oesophageal reflux disease, where 
sensitisation is already established and, therefore, it is important to determine whether 
the tVNS can reverse sensitisation that has been established. If proven, the ability to 
reverse oesophageal pain sensitivity gives tVNS a dual mechanism of action (i.e. 
prevention and reversal of oesophageal hypersensitivity), thus strengthening the 
rationale for translation into clinical practice. The focus on enhancing the reversal of 
oesophageal pain sensitivity is especially important when taking into consideration the 
larger therapeutic window to use this intervention when compared with prophylactic 
stimulation during reflux episodes only. The pivotal experiments evaluating the role of 
VNS in reversing acid-induced oesophageal pain hypersensitivity have not been 
conducted. Our aim is, therefore, to use the model above of acid-induced oesophageal 
pain hypersensitivity, to determine the effect of t-VNS on the reversal of pain 




We, therefore, hypothesised that t-VNS reverses the development of acid-induced 
















Figure 25: Electrical vagal nerve stimulation. Panel A (left) depicts a traditional invasive vagal nerve 
























Figure 26– The effect of active and sham tVNS on the development of oesophageal pain hypersensitivity, 
derived from change in pain thresholds. Mixed effects linear regression, controlling for age and gender, 
demonstrated that VNS prevented the development of acid-induced esophageal hypersensitivity in 












We proposed to undertake a study evaluating the use of t-VNS in our validated model of 
oesophageal pain hypersensitivity. The study flowchart is summarised in figure 28.  
Sample size 
Based on our extensive experience with this model of acid-induced oesophageal 
hypersensitivity, we have produced summary data demonstrating that subjects have a 
mean reduction in pain thresholds of -14.3% +/- standard deviation of 16.4% at T120 
relative to baseline. Seventeen subjects would provide 90% power at a two-sided 
significance level of 0.05 to detect a difference of 14.3%, i.e. to prevent sensitisation in 















Visit 1  
Psychological profiling and autonomic nervous system measurements 
 
 Validated questionnaires assessing anxiety (Hospital Anxiety and Depression Scale and 
Spielberger State/Trait anxiety) were completed. To define the anatomical landmarks of 
the oesophagus (i.e. position of the lower oesophageal sphincter, if the recruited subject 
has not been studied before using this model), then high-resolution oesophageal 
manometry was undertaken first to define this. At baseline, and continuously after that, 
 
Effect of Transcutaneous Vagal Nerve Stimulation (t-VNS) on the maintenance of oesophageal pain 
hypersensitivity  
45 Healthy volunteers
Parasympathetic nervous system monitoring at baseline and continuously thereafter 
Subjects intubated with oesophageal catheter and baseline oesophageal sensory and pain thresholds to 
electrical stimulation measured in the proximal oesophagus.








proximal  oesophageal sensory & pain threshold to electrical stimulation
At  T90  and T120
Crossover with at least 2 weeks between visits
Figure 6 – Proposed study flowchart investigating the effect of t-VNS  on reducing oesophageal pain 











measurement of PNS tone were made using the non-invasive Neuroscope system, a 
technologically advanced biosignals acquisition system that allows for validated 
measurement of efferent (cardiac vagal tone) of the PNS (172). This monitoring also 
provides an additional safety aspect to the study. 
 
Randomisation Procedures  
 The randomisation of subjects to either active or sham intervention was performed 
using approved statistical software (www.randomization.com). Subjects were not told 
which intervention (active/sham) they have been randomised to. 
High-resolution Manometry 
 The ManoScan 360™ High-Resolution Manometry system from Sierra Scientific was 
used. A specialised HRM catheter sheathed in a single-use sleeve was inserted through 
the nostril into the oesophagus until the distal end of the catheter is resting in the 
proximal stomach. The catheter is then taped to the nose. Lower oesophageal sphincter 
(LOS) position, in terms of cm from the nostril, were recorded and used to guide insertion 
of further catheters in the next steps of the study.  
Acid infusion and pain tolerance measurements  
Intra-oesophageal intubation of participants was undertaken using a specialised 
catheter, containing a distal infusion port and a pair of silver-silver chloride bipolar ring 
electrodes (3 mm diameter catheter (Unisensor AG, Ch-8544 Attikon, Switzerland). 
Oesophageal sensory testing was performed via a pair of silver-silver chloride bipolar ring 
electrodes (inter-electrode distance 1 cm), situated 16 cm proximal to the tip of a 3 mm 
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diameter catheter. Following identification of the lower oesophageal sphincter, using 
high-resolution manometry, electrical stimulation was performed 17 cm proximal to the 
lower oesophageal sphincter. Electrodes were connected to an electrical stimulator, and 
stimuli are delivered at a frequency of 0.5 Hz, using square wave pulses (0.5 s duration), 
at intensities varying between 0 and 90 mA. The intensity of stimulation was increased 
incrementally by two mA, and each subject were asked to report both, the sensory 
threshold (visual analogue scale (VAS) of 1 out of 10), and when they cannot tolerate any 
further increase (VAS of 7 out of 10), that is defined as pain tolerance threshold (PTT). 
The electrical stimulation was immediately stopped when PTT is reached. 
 Electrical sensory and pain tolerance testing were undertaken in the proximal 
oesophagus at baseline (T0) and, at 60 minutes (T60), 90 minutes (T90) and 120 minutes 
(T120) after starting distal oesophageal acid infusion of 0.15M hydrochloric acid (T0-30) 
(Stepping Hill Hospital, Stockport) using a syringe pump (KDS Scientific 100, Linton 
Instrumentation, Palgrave, UK). At T60, non-sensitisers were excluded. Non-sensitisers 
are defined as having a post-acid infusion reduction in upper oesophageal PTT of ≤ 6 mA 
at T60, as previously defined by Sharma et al. (169).  
Active and sham vagal stimulation 
To evaluate the effect of t-VNS on enhancing the recovery of OPH, after acid infusion 
participants were randomised, in a single-blinded manner (participants were blinded to 
the position of the active intervention in the study), to receive either active t-VNS (placed 
on the region of the outer ear supplied by the auricular branch of the vagus) or sham t-
VNS (t-VNS module placed on the area located below the tragus, supplied by the Great 
Auricular nerve) (Figure 28). The device delivers rectangular pulses (250 μS, 25 Hz) (7) 
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(NEMOS, Cerbomed GmbH, Erlangen, Germany (CE marked). Both intervention 
(active/sham) lasted for 30 minutes (T60-T90). We then repeated pain tolerance 
measurements at T60, T90 and T120 (Figure 29). The sham intervention was adopted 
after it was recently validated in a published clinical trial using tVNS and paced deep 
breathing to modulate gastroduodenal motility, only active stimulation and not sham 
significantly increased vagal tone (192). 
Blinding 
Participants were blinded to the position of the active intervention in the study and were 
told that we are measuring the effect of stimulation on two distinct nerves. Analysis of 
results was performed by an investigator blinded to the type of intervention. Participants 




Figure 28: Nerve supply of the outer ear. The ellipse markings show the proposed positioning of the electrodes for 
















Following a period of no less than two weeks, to reduce any potential carryover effect, 
participants were crossed over and restudied to receive the intervention they did not 
receive in visit 1. 
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Schedule of assessment: 
Assessment  Visit 1 Visit 2 
Medical and social history 
taking 
x  
Questionnaires  x x 




Manometry   
x  
ANS monitoring  x x 
PTT measurements  x x 










Primary outcome measure  
• Pain tolerance to electrical stimulation at T120 
Secondary outcome measures  
• Pain tolerance thresholds at T60, T90  
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• Effect of t-VNS on ANS variables  
 
Data Analysis  
 
Changes in pain tolerance thresholds were analysed using linear mixed-effects 
regression model with a maximum restricted likelihood (fixed effects: time, 
interventions, i.e. active t-VNS vs sham t-VNS; random effect = subject) with T0 
thresholds accounted for in the model as zero to yield a regression coefficient for 
intervention effect. All analyses were two-sided, and a statistical criterion of α<0.05 were 
adopted. Analyses were conducted using the propriety software Stata /SE version 10.1 




Healthy subjects, aged 18-41, were recruited from the staff and local population around 
Queen Mary University of London by advertisement and poster only or from our existing 
databases of healthy volunteers who have previously agreed to have their contacted 
details included in the database and expressed interest in being informed of other 
studies in the institute. Vulnerable groups were not be approached. We recruited 






1. Healthy volunteers, aged 18-60, from the staff of Queen Mary, University of London 
and the local population.  
2. Inclusion was determined based on availability, with no prior selection bias included. 
They should be able to attend the Wingate Institute for at least 2 x 2.5-3 hours sessions.  
 
Exclusion criteria: 
1.  Participants are unable to provide informed consent (e.g. not English speaking) 
2. Participants with any systemic disease or medications that may influence the 
autonomic nervous system (e.g. beta-agonists or Parkinson’s disease) 
3. Participants with a history of cardiovascular conduction problems 
4. Participants who are pregnant 
5. Participants who have tinnitus 
6. Participants with cochlear implants 
7. Those with reflux disease 











Twenty-five participants (12 male, mean age 26.4 years, range 19-41) were recruited. In 
total, 7 participants (4 male, mean age 27.7 years, range 19-36) were excluded with five 
classified as non-sensitizers, and a further 2 participants did not tolerate naso-
oesophageal intubation, see flowchart below. This was an expected rate of non-
sensitization based on our previous work, thus leaving, 18 participants (8 male, mean 





Figure 30: FLOWCHART - The effect of vagus nerve stimulation on reversing established oesophageal 
pain hypersensitivity. Sensitisers and non-sensitizers were defined based on their proximal oesophagal 
pain thresholds to distal oesophageal acidification during their sham t-VNS visit. Participants who failed 
to sensitise at the sham t-VNS visit were excluded from subsequent analysis. There was a washout 












Vagus nerve stimulation reverses established oesophageal hypersensitivity 
 
The most common symptom reported with acid infusion was nausea (4/18, 22.2%). 
Absolute threshold data at (T0) and after acid infusion (T60, T90, T120) are shown in 
Table 14. There were no differences in absolute values of PTT at T0 or T60 in participants 
receiving t-VNS or sham VNS (T0 mean (SD) t-VNS 38.7mA (12.6) vs sham t-VNS 37.3mA 
(15.7), p=0.69, T60 t-VNS 28.7mA (11)) vs sham t-VNS 27.2mA (11.2), p=0.55). Relative 
to the T60 time-point, there was an increase in PTT with t-VNS at T90 of 3mA (95% CI 1 
- 5.1) in comparison to sham t-VNS of 0.7 mA (95% CI -1 – 2.3). Similarly, at T120, there 
was an increase in PTT with t-VNS of 3.8mA (95% CI 1.5 - 6.1) in comparison to sham t-
VNS, 1.3mA (95% CI -0.4 – 3). Mixed-effects regression showed a significant effect for t-





Figure 3124: The effect of t-VNS  and sham t-VNS on the reversing established oesophageal pain 
hypersensitivity, derived from the paired change in pain thresholds (mean ± standard error of the mean), 
in the proximal oesophagus at T60, T90 and T120, with mixed-effects regression showing a coefficient 














Table 14: Absolute values for proximal oesophageal PTT before (T0) and after (T60, T90 and T120) acid 
infusion with (a) t-VNS and (b) sham t-VNS delivered after acid infusion.  
 
a. Pain tolerance thresholds – t-VNS after oesophageal acidification 
 T0 T60 T90 T120 
Pain thresholds: 
mean (SD) mA 
38.7 (12.6) 28.7 (11.0) 32.1 (16.5) 34.5 (20.7) 
b. Pain tolerance thresholds– sham t-VNS after oesophageal acidification 
Pain thresholds: 
mean (SD) mA 
















Effect of tVNS on cardiac vagal tone 
Using a Repeated Measures general linear model, I could not find a statistically significant 




Table 15: Absolute values of cardiac vagal tone during the different epochs of the experiment  
 
Active Sham 
Baseline 9.61 11.30 
Acid infusion 9.8 9.42 
Sensitization 12.17 11.30 
Stimulation/sham 10.58 12.55 










Table 16: Repeated Measures general linear model failed to detect a statistically significant effect of vagal 
nerve stimulation on cardiac vagal tone. df: degree of freedom, tVNS: transcutaneous vagal nerve 
stimulation.   
 
Source Type III Sum of Squares df Mean Square F p-value 
Intercept 22362.624 1 22362.624 197.503 .000 
tVNS 71.080 1 71.080 .628 .434 






Relationship between cardiac vagal tone and sensitisation  
There was no significant correlation between change in cardiac vagal tone and the 
degree of sensitisation, see figure 33.  
 
Figure 25: Correlation between the change in cardiac vagal tone (DELTA_CVT) and change in pain 










This study suggests that t-VNS reverses established acid-induced oesophageal pain 
hypersensitivity. This effect is likely mediated by vagal modulation of the central 
nociceptive network.  It is also possible, although less likely that the  effect could also be 
mediated in part via an anti-inflammatory pathway(193, 194). During systemic 
inflammation, the CNS is activated by vagal afferents.  Following input integration, the 
coeliac ganglion activates the vagal efferent, which acts to modulate the immune 
response in the spleen, leading to a triggering of splenic adrenergic neurons which in 
turn cause a release of noradrenaline and subsequently acetylcholine (ACh(194)).  ACh 
binds to the alfa-7nACh receptor localised to macrophages, which in turn decreases the 
release of inflammatory cytokines, including tumour necrosis factor. Thus, it is thought 
that the vagal nerve is a key modulator of inflammation.  Furthermore, during GI 
inflammation or pain, the vagal afferent fires to the CNS, which in turn leads to the 
activation of the vagal efferent which targets myenteric neurons of the intestinal wall.  
This leads to the subsequent release of ACh from enteric neurons, serving a similar 
immunomodulatory pathway as to when systemic inflammation occurs(194). 
The articular branch of the vagal nerve stimulated in this study, is a pure afferent nerve 
(195); thus, most likely, the anti-nociceptive effect seen in this study is centrally 
mediated. The anti-inflammatory effect of vagal activation require efferent modulation 
which is not seen in this study.  
 Functional neuroimaging studies suggest that t-VNS modulates areas of the brain 
associated with central pain neuromatrix such as the thalamus, orbitofrontal cortex, 
cerebellum, hypothalamus, medulla and the limbic system (196, 197). For instance, 
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implanted VNS has been shown to result in the insula and cortical activation. Those areas 
have been observed to be important in mediating acid-induced oesophageal pain in 
healthy participants and in patients with gastro-oesophageal reflux disease (198-200). 
Moreover, t-VNS is associated with an increase in insula activity and a reduction in the 
amygdala and hippocampal activity (201). It has been recently illustrated how higher 
resting parasympathetic CVT conveys greater network connectivity in several subcortical 
regions implicated in descending analgesia, including the anterior insula, amygdala and 
hypothalamus, suggesting a prospective neural mechanism for t-VNS induced anti-
nociception (202).  
 
In previous studies, our group has demonstrated that the oesophageal hyperalgesia that 
develops in the non-acid exposed proximal oesophagus most likely occurs due to central 
sensitisation at the dorsal horn of spinal cord (203). Central sensitisation reflects 
enhanced nociception through three broad mechanisms, namely, temporal summation, 
increased activation of nociceptive facilitatory pathways or impairment of descending 
pain inhibitory pathways. Dysfunction within the descending pathways may particularly 
promote and maintain central sensitisation (204). Within the brainstem, primary afferent 
vagal fibres terminate in the nucleus tractus solitarius, which also contributes to  
descending inhibitory pathways which form a spinal-bulbo-spinal anti-nociceptive circuit 
(205). The central analgesic effect of VNS has been proposed to increase such 
descending pain modulatory pathways (206). However, other studies have shown that 
the vagus nerve modulates nociceptive processing in both the spinal cord and the brain. 
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For instance, nociceptive transmission at the spinal dorsal horn can be inhibited by the 
electrical stimulation of abdominal vagal afferents (207, 208).  
 
The antinociceptive effect could also be in part mediated via a local anti-inflammatory 
effect. The vagus nerve effect on inflammation is mediated by acetylcholine or 
noradrenaline, also known as the cholinergic anti-inflammatory pathway (209-211). In 
the context of t-VNS, several studies have shown short term stimulation exerts an anti-
inflammatory effect (212, 213). Besides, the vagus nerve interacts with the 
hypothalamic-pituitary-adrenal axis, which results in the release of cortisol inhibiting the 
proliferation of pro-inflammatory cells (194). Following acid-induced oesophageal cell 




Our findings have several therapeutic implications. Heartburn and chest pain are 
common symptoms in functional oesophageal disorders which are mediated, in part, by 
oesophageal hypersensitivity (214, 215). Although proton pump inhibitors (PPIs) are the 
gold standard for the treatment of gastro-oesophageal reflux disease, a substantial 
proportion of such patients fail to respond (216). Non-pharmacological interventions are 
increasingly being sought to treat chronic pain disorders. Coupled with the data from our 
study, and an established favourable safety profile, t-VNS could represent an attractive 
non-invasive neuromodulatory intervention that warrants further study in this group. 
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This is particularly important given that we demonstrated that t-VNS could reverse 
established oesophageal hypersensitivity.  
 
Our study is subject to several limitations. Within any cross-over design, there is potential 
for a carryover effect, although we attempted to ameliorate this by using at least two 
weeks between study visits (217). We used electrical stimulation to investigate visceral 
oesophageal pain which may be considered non-physiological. The main aim of this study 
is to investigate pain hypersensitivity caused by central sensitisation. An electric stimulus 
can bypass the several types of nociceptive receptors to initiate an afferent signal 
transmitted to the dorsal horn of the spinal cord, where central sensitisation is thought 
to take place which makes it a convenient stimulus modality to use and the model used 
in our study has been well validated to induce secondary hyperalgesia most likely due 
central sensitisation.  Finally, this is a study in young, healthy volunteers. Further studies 
are needed to see if this applies to patients with evidence of oesophageal pain 
hypersensitivity.  
 
In conclusion, non-invasive vagal nerve stimulation could reverse an experimentally 
induced oesophageal hypersensitivity in healthy volunteers, under strict laboratory 
settings. Further studies are needed to see if the effect is significant in patients with 
clinical manifestations of oesophageal pain hypersensitivity, such as those with 






Chapter 7:  
Summary of findings and future directions 
 
Summary of findings  
Pain hypersensitivity is a common finding in functional gastrointestinal disorders. It 
represents a challenge for several reasons. Firstly, it is a common finding that reduces 
the quality of life, drives anxiety and causes health care seeking visits (9, 218).  One 
example is oesophageal pain in patients who are adequately treated with acid-reducing 
medications that may persist in 10- 40 % depending on the study (9). When taking into 
consideration the prevalence of gastroesophageal reflux disease, ten per cent can add 
an important burden to the healthcare system and can cause an important reduction in 
the quality of life.   
Functional gastrointestinal disorders are benign in nature; thus, a treatment designed to 
treat such disorders should have a good safety profile to be justified.  Given the chronicity 
of such conditions and the large prevalence, a proposed treatment should also be 
reasonably cheap and preferably self-applied.  
Another challenge is that functional gastrointestinal disorders are grouped based on 
clinical symptoms and not by well explained physiopathological mechanisms. Such 
classification will inevitably result in a large heterogeneity within this group.  
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This thesis aims to contribute to a better understanding of visceral pain hypersensitivity 
and to propose feasible interventions to be developed further.  
 
In the 1st chapter, I tried to present a relevant overview of the biology of pain. I 
introduced concepts such as the pain network, definitions of peripheral and central 
sensitisation. There are notable observations that are likely to facilitate understanding 
of pain hypersensitivity. The important role of descending pathways in regulating pain is 
also discussed. Descending pathways are complex and influenced by several factors 
ranging from local spinal mechanisms to complex interactions of multiple inputs from 
emotional, autonomic, hormonal and cortical regions.  We also observe an 
interconnected pain and autonomic network that shares many of its key structures.  
Such a complex pain network likely means that several pathways that can override each 
other depending on the context.  This will inevitably mean that there is a heterogeneous 
group of patients with a similar final complaint e.g. pain. 
There are peripheral and central causes of pain hypersensitivity. However, the role of 
peripheral causes is less evident in functional gastrointestinal disorders. For example, 
Guy Boeckxstaens and colleagues studied the effect of the mast cell stabiliser / H1 
receptor antagonist ketotifen on rectal pain hypersensitivity in IBS. The medication was 
superior to placebo in abdominal pain reduction in a controlled study; however, there 
was no difference in the spontaneous histamine and tryptase release measured in the 
supernatant of rectal biopsies before and after treatment(219). One interpretation is 
that the effect of ketotifen on pain hypersensitivity was centrally mediated via H1 
receptor antagonism.  
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Descending pain inhibition can be very pronounced, for example, the within-group 
difference in pain threshold in gunshot wounds in soldiers. This observation highlights 
the potential of descending pathways in controlling pain that we could potentially target 
as a therapeutic pathway.  
The overall pain experience is complex. It is a result of complex and intricate interaction 
between the primary stimulus (if there is one), the central pain network, autonomic 
network, emotional and cognitive centres.  
Emotions have an important influence on descending regulation of pain (220). Several 
emotions express clear autonomic responses. James and Lange suggested that emotions 
are the by-products of biological feedback from the periphery (63, 64). They argue that 
for example, an increased heart rate, sweaty hands and shallow breathing will produce 
emotions consistent with this physical status, such as fear.  Regardless of the 
directionality of the cause and effect between emotion and autonomic response, the 
association is clearly there. One could suggest that a conditioned reflex is formed 
between specific emotional responses and physiological status. If this line of thinking is 
sound, then inducing a physiological state that is consistent with relaxation, will likely 
induce relaxation. For example, slow deep breathing causes reliable parasympathetic 
nervous system activation with slowing down of breathing and heart rate. This, in turn, 
can activate descending pathways to increase the pain threshold.  This mechanism of 
action will also contribute to other non-pharmacological analgesic interventions such as 
massage therapy. Muscle tone feedback likely contributes to the emotional status; one 
example on that is benzodiazepines that are both anxiolytics and muscle relaxants.  
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In chapter 2, I investigate the autonomic effect of two interventions used successfully 
previously by our group to reduce experimental oesophageal pain. Those are attention 
or distraction (30)and slow deep breathing(188). In this study, I demonstrated that there 
is a distinct autonomic pattern between the two interventions. 
 Slow deep breathing increased the parasympathetic tone; however, this effect was 
short-lived and ceased immediately after returning to normal breathing. Several 
plausible mechanisms could mediate the effect of slow deep breathing on pain. First, the 
explanation proposed by Botha and colleagues suggested that the effect is mediated by 
an efferent vagal mechanism. This conclusion was supported by diminishing the anti-
nociceptive effect of slow deep breathing with concomitant use of atropine. Atropine is 
known to inhibit the action of acetylcholine that is the main neurotransmitter on the 
efferent vagal. Although this explanation has its merits, there is one limitation. Atropine 
is also known to increase heart rate and possibility respiratory rate by an antimuscarinic 
action. This antimuscarinic action could have increased sensitisation in the atropine 
group making them more sensitised than the slow deep breathing group. There was no 
control group to see if the use of atropine alone could increase sensitisation.  
The other possible mechanism is by distraction. Slow deep breathing could have a 
distractive effect on participants. The control group were asked to count their breathing 
frequency, which could act as a control for distraction. It is not known if the two 
interventions had the same distractive effect.  
Another possible mechanism is an afferent one. Slow deep breathing has well described 
effects on autonomic reflexes such as the cardiopulmonary coupling which is mediated 
via the vagal nerve. It is plausible that parasympathetic activation induced by slow deep 
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breathing may trigger autonomic influence on descending pathway acting on pain 
receptive filed in the spinal cord, this action will be therefore independent of the efferent 
vagus.  
The other intervention studied in chapter two is attention. This has previously shown to 
reduce oesophageal pain. The mechanism is likely cognitive and related to diverting 
attention away from the pain stimulus (30). Some studies suggest that cognitive tasks, 
such as placebo analgesia could trigger descending pain inhibition(221).  However, it is 
not clear if attention directly triggers descending inhibitory pathways.  
 
Although it appears that slow deep breathing and attention produce distinct autonomic 
signatures, it is still possible that both can trigger descending inhibition of pain. For that 
reason, it plausible to suggest a synergistic effect when combining the two interventions. 
Such a combined action is likely achieved by meditation exercises that combine both 
breathing techniques and distraction.  
 
In chapter 3, I studied the top-down control of pain. Admittedly, there is no precise way 
of pinpointing the exact central structure that contributes the most of descending pain 
modulation. As previously mentioned, the control over descending pathways is intricate. 
It involves multiple structures that can tap into the system to inhibit or facilitate pain. As 
a general rule, higher structures can alter the overall balance depending on the situation. 
For example, chronic anxiety and physically intense sports share similar autonomic 
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profile, which is a sympathetic nervous system activation. However, the pain threshold 
set by descending modulation is likely to be different in those two situations (220). 
I hypothesised that in functional gastrointestinal disorder, the descending inhibition of 
pain is impaired. Conditioned pain modulation is a way of measuring this pathway(222).  
We showed that there is a statistically significant and clinically important difference in 
descending inhibition between patients with irritable bowel syndrome and healthy 
controls. Patients were five times more likely to have an impaired conditioned pain 
modulation than healthy control. This level of significant separation between IBS patients 
and healthy controls is rarely seen in clinical studies. This odd’s ratio is very similar to 
that of post-infectious IBS, which is now accepted as a distinct entity in IBS (223). These 
findings have several implications. First, they emphasise the descending pain pathways 
role in functional pain. Secondly, conditioned pain modulation can help to classify 
patients by physio pathological factors. Such classification aims to reduce heterogeneity 
in clinical trials and mechanistic studies.  Third, those findings suggest that descending 
pain modulatory pathways are potential targets in functional visceral pain; this may be 
achieved by using centrally acting medications such as antidepressants active via the 
noradrenergic pathways (tapentadol, duloxetine, reboxetine and nortriptyline in low 
doses) . Finally, conditioned pain modulation can also act as an objective endpoint in 
clinical trials. Based on the highly significant difference between patients and healthy 
control, further studies are warranted to better understand the relationship between 




In chapter 4, I elaborated on the relationship between descending pain modulation and 
experimental oesophageal hypersensitivity. The main finding was that baseline 
conditioned pain modulation was a strong predictor of sensitisation to experimental acid 
infusion.  Those findings are in line with the observations of Wider-Smith and colleagues 
who demonstrated that baseline conditioned pain modulation can predict postsurgical 
pain (148). Another observation in this study was that participants who sensitised the 
most also increased conditioned pain modulation the most in percentage terms. 
However, they had a low baseline; thus, the overall magnitude of descending pain 
inhibition was low in absolute terms. This suggests a ceiling effect of conditioned pain 
modulation in those participants.  
 In chapter 5, I performed a systematic review, to gather information regarding the use 
of vagal nerve stimulation in pain. There was a small but significant overall effect. This 
small effect size was predicted because of the important heterogeneity of the studies. 
Noticeably, there was an important variation in stimulation periods and parameters. 
There was a positive effect despite the variability of stimulation parameters, site of 
stimulation, conditioned studied, this suggest a non-specific mechanism. The effect is 
most likely afferent because of the anatomy of the stimulated nerves. The auricular 
branch of the vagal is a pure afferent nerve(195). Reassuringly, there was no important 
side effect reported with the use of this intervention.  
In chapter 6, I studied the effect of non-invasive vagal nerve stimulation in a validated 
human model of oesophageal pain hypersensitivity. I used a device designed to stimulate 
the auricular branch of the vagal nerve. My results suggest that vagal nerve stimulation 
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could reverse temporarily acid-induced oesophageal pain hypersensitivity faster than 
sham stimulation. This effect was independent of the efferent vagal effect.  
I suggest that the effect of vagal nerve stimulation is mediated at the level of the central 
nervous system. Despite a careful review of the published literature on the anti-
nociceptive effect of vagal nerve stimulation, the exact mechanism remains elusive.  
From published literature, we notice a positive effect of vagal nerve stimulation on 
nociception despite stark variation in stimulation parameters. In my opinion, one 
possible mechanism of how non-invasive vagal nerve stimulation could exert an anti-
nociceptive effect would be through competition of afferent stimulation with ascending 
pain signals. This conceptual theory would resemble, to some extent, what has been 
suggested by Melzack and Wall(41). Melzack and Wall suggested a gate-like effect at the 
level of the spinal cord where non-painful stimuli compete with painful ones resulting in 
reduced pain transmissions. Several interconnecting steps explain this phenomenon, 
such as interneurons at the level of the dorsal horn. It is plausible that a similar 
mechanism may exist at the level of the brainstem where stimulation of the auricular 
branch of the vagal nerve is transmitted. Non-painful stimuli generated by vagal nerve 
stimulation may compete with the painful stimuli resulting in reduced transmission. Such 
a mechanism will explain the non-specific nature of this intervention. Another possibility 
is that the non-specific nature of vagal nerve stimulation at the level of the brain stem 




Future directions  
Based on the results of my program of the research described in this thesis, there are 
several studies warranted. 
Based on the study in chapter one, we suggest a clinical trial to investigate a combined 
intervention with distraction and slow deep breathing in patients with evidence of 
oesophageal reflux hypersensitivity. If effective, this is a safe and low-cost intervention 
that is likely to improve the quality of life of those patients and reduce costs for 
healthcare providers.  This will be a 6-weeks randomised study. The active group will be 
assigned to once-daily protein pump inhibitor and specially designed mindfulness 
exercise with slow deep breathing paradigm using a telephone application for 30 
minutes twice daily. Focusing on the present or focusing of breathing can act as a form 
of distraction.  The other group will be assigned to double dose of protein pump 
inhibitors for six weeks (common clinical practice).  The outcome measure will be specific 
gastroesophageal reflux disease validated questioners and quality of life questioners.  
Based on the studies in the third and fourth chapters, there is a need to investigate 
conditioning pain modulation in patients with visceral pain hypersensitivity to see if 
simple baseline conditioned pain modulation test can predict patients with oesophageal 
pain hypersensitivity proved by reflux monitoring (214). This will have a prognostic value 
in those patients when choosing the appropriate treatment.  
It is feasible to investigate the effect of centrally acting medications such as several 
classes of antidepressants, anxiolytic and muscle relaxants on conditioned pain 
modulation in patients with oesophageal pain hypersensitivity. Condition pain 
modulation can be used to predict the success of therapy of medications with a potential 
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effect of descending pain inhibition. For example,   in diabetic neuropathy, conditioned 
pain modulation could predict response to the serotonin and norepinephrine reuptake 
inhibitor duloxetine and the mu-opioid receptor agonist and noradrenaline reuptake 
inhibitor tapentadol(151, 152). 
Another future study will aim to investigate the effect of vagal nerve stimulation on 
conditioned pain modulation in patients with oesophageal reflux hypersensitivity in a 
sham-controlled trial. We will measure conditioned pain modulation at baseline, then 
randomise patients to either active transcutaneous vagal nerve stimulation or sham 
stimulation for 30 min twice per day for six weeks. The main outcome measure will be 
conditioned pain modulation after active or sham treatment.  
 
Limitations  
Applicability to the clinical population  
All experimental studies were performed on healthy volunteers that may limit 
applicability to patients. The reason for choosing healthy volunteers was to avoid the 
multiple confounders usually found in patients with visceral hypersensitivity. Those 
patients usually display several concomitant functional pain syndromes which makes it 
very challenging to interpret data. Controlling confounders in disease population such as 
the intensity of symptoms, psychological and social factors, medications and other 
medical conditions would not have been feasible within the timeline of this PhD thesis.   
To understand the temporal relationship between conditioned pain modulation at 
baseline and pain hypersensitivity, it is necessary to measure conditioned pain 
modulation before and after the disease. In clinical settings, pain hypersensitivity is a 
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chronic condition; thus, it is not possible to measure conditioned pain modulation before 
the onset of the disease. Studying conditioned pain modulation in healthy volunteers 
before and after experimentally induced pain hypersensitivity may help to establish a 
temporal relationship.  
 
Limitations of selected methods 
The acid-induced oesophageal pain hypersensitivity model 
 This model uses a defined noxious stimulus to induce oesophageal pain hypersensitivity. 
However, the module is relatively invasive and creates unpleasantness and anxiety. 
Anxiety and unpleasantness could contribute to sensitisation or hypervigilance to the 
painful stimulus. A locally defined noxious stimulus may contribute to pain in many 
diseases such as non-erosive reflux disease, where there is an increased acid exposure 
in the lower oesophagus. However, most functional gastrointestinal disorders lack a 
defined sensitising stimulus. This may also affect the applicability of this model to all 
functional pain conditions.  
Electric oesophageal pain as a testing stimulus in Conditioned Pain Modulation paradigm 
The use of electric oesophageal pain stimulus has not been previously used in a 
conditioned pain modulation paradigm.  Electrical pain stimulus is separately validated 
in both the acid-induced oesophageal model and in Conditioned pain modulation 
paradigm (55, 224). The choice of oesophageal location of the stimulus was chosen for 
several reasons: 1) Participants had an inserted catheter for acid infusion, which also 
contain a stimulation electrode. 2) The location is relevant to our clinical question that is 
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concerned with visceral pain. 3) Choosing another stimulus would have prolonged the 
study and added another unpleasant experience that is not necessary.  
Using transcutaneous vagal nerve stimulation 
Then devise used in chapter 6 is the NEMOS device. This device has an electrode that is 
attached to the concha of the ear. As per chapter 5, there are no robust data to favour 
specific stimulation parameter. The stimulation was set at the lowest tactile sensation 
felt by participants. This meant different intensities for different participants. There is 
marked variability in the subjective experience of the stimulus in between individuals, a 
tactile sensation for some can be painful for others. We set the intensity at the sensory 
threshold to avoid an unpleasant sensation. A painful sensation caused by stimulation 




Studies in this thesis explored the relationship between the central modulation of pain 
and visceral pain hypersensitivity. I have presented evidence that central control of pain 
is inhibited in conditions with visceral pain hypersensitivity such as irritable bowel 
syndrome. I have also demonstrated that baseline top-down control of pain could predict 
the degree of developing pain hypersensitivity in healthy individuals. I then 
demonstrated that non-invasive vagal nerve stimulation could reverse experimental pain 
hypersensitivity, likely by a central mechanism. These studies may be helpful in planning 
future studies in patients with visceral pain hypersensitivity which may be helpful in 
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